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Abstract 
Protein depletion is a key approach to understanding functions of a protein in a biological system. 
We recently developed the Trim-Away approach in order to rapidly degrade endogenous proteins 
without prior modification. Trim-Away is based on the ubiquitin ligase and Fc receptor TRIM21, 
which recognizes antibody-bound proteins and targets them for degradation by the proteasome. In a 
typical Trim-Away experiment, protein degradation is achieved in three steps: first, introduction of an 
antibody against the target protein; second, recruitment of endogenous or exogenous / 
overexpressed TRIM21 to the antibody-bound target protein; and third, proteasome-mediated 
degradation of the target protein, antibody and TRIM21 complex. Protein degradation by Trim-Away 
is acute and rapid, with half-lives of around 10-20 minutes. The major advantages of Trim-Away over 
other protein degradation methods are that it can be applied to any endogenous protein without 
prior modification; that it uses conventional antibodies which are widely available; and that it can be 
applied to a wide range of cell types including non-dividing primary human cells, where other loss-of-
function assays are challenging.  In this Protocol, we describe the detailed procedures for antibody 
preparation and delivery in mouse oocytes and cultured cells via microinjection and electroporation. 
In addition, we provide recommendations for antibody selection and validation and for generating 
TRIM21 over-expressing cell lines for cases where endogenous TRIM21 is limited. A typical Trim-
Away experiment takes just a few hours. 
 
Introduction 
Protein depletion is one of the key tools for studying protein functions in cells and tissues and can be 
achieved by either interfering with protein synthesis or by inducing protein degradation. Protein 
synthesis can be blocked at various levels. At the genomic level, protein-coding genes can be 
disrupted using genome-editing technologies such as zinc-finger nucleases (ZFN), transcription 
activator-like effector nucleases (TALEN) and the clustered regularly interspaced short palindromic 
repeats (CRISPR)-Cas system. These technologies are all based on nucleases that can be targeted to a 
specific DNA sequence and introduce a frame-shift mutation, a premature stop codon, or delete the 
coding sequence1. At the post-transcriptional level, messenger RNAs (mRNAs) can be targeted for 
degradation using RNA interference (RNAi). To this end, sequence-specific small interfering RNAs 
(siRNA) or short hairpin RNAs (shRNA) are introduced into cells. These become incorporated into 
RNA-induced silencing complexes (RISC), which bind to and degrade the target mRNA2. At the 
translational level, morpholino oligomers can be used to block the translation of mRNAs. These 
antisense oligonucleotides bind to the target mRNA and block the progression of the translation 
initiation complex from the 5’ cap to the start codon3.  
While these techniques have been proven to be highly useful for studying various genes in different 
model systems, a common major limitation is that they are not suitable to deplete already 
synthesized proteins. In both metabolically inactive and long-lived metabolically active cells, certain 
proteins – particularly those in essential cellular structures – can persist for years after translation4. 
These long-lived proteins cannot be depleted by blocking protein synthesis at the gene or mRNA 
level. Another limitation of methods that act at the gene or mRNA level is the long delay between 
the time of their application and actual protein depletion, which is typically in the range of days. 
These methods are therefore not well suitable to investigate short-lived biological processes.  For 
example, many regulatory proteins have multiple functions during different stages of mitosis, which 
takes only about 1 hour in HeLa cells5. If protein degradation is delayed, it is difficult to determine if 
the phenotypes are a direct consequence of protein depletion or a secondary consequence of earlier 
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defects6. Delays may also allow cells to activate compensatory mechanisms, which may modify or 
even mask the phenotypes7. 
To overcome these challenges, several methods have been developed that act directly on the protein 
level, targeting the protein itself for degradation. Some of these methods are based on controlling 
protein stability, for instance by fusing the target protein to destabilizing domains that are controlled 
by ligands8,9. Others are based on recruiting SKP1-CUL1-F-box (SCF) E3 ubiquitin ligases to the target 
protein, such as binding of an auxin-inducible degron to the F-box protein TIR1, and binding of GFP-
tagged proteins to a GFP nanobody fused to the F-box domain of Slmb10, 11. Proteins can also be 
perturbed acutely by knock-sideways approaches, in which proteins are targeted away from their 
principle site of action, for instance by tethering them to mitochondria12.  However, all of these 
assays require the endogenous protein to be first replaced by a modified variant. They are hence not 
suitable for studying protein functions in all cell types. For instance, application of these methods in 
non-dividing primary cells would often require the generation of transgenic animals. This is time-
consuming and not feasible for many species. For tag-free degradation, ligand- and peptide-based 
techniques have been developed, but the number of proteins that can be targeted with these 
methods is very limited13,14. 
To achieve acute depletion of any endogenous protein without prior modification, we recently 
developed a post-translational protein depletion method, which we called ‘Trim-Away’15. Trim-Away 
relies on an E3 ubiquitin ligase called TRIM2116. TRIM21 is involved in the intracellular immune 
response: it binds to antibody-bound pathogens and proteopathic agents and targets them for 
degradation17-19. The precise mode of action of TRIM21 is not yet fully understood, but it involves 
binding of TRIM21 to the Fc-region of an antibody and subsequent autoubiquitination of TRIM21. In 
a Trim-Away experiment, the high affinity of TRIM21 to the Fc-region of an antibody is exploited to 
target endogenous proteins for degradation. An antibody against the target protein is introduced, 
TRIM21 binds to the antibody-bound target protein and triggers the proteasome-mediated 
degradation of the antibody-antigen complex together with TRIM2120,21. Trim-Away has enabled us 
to degrade a wide variety of proteins within minutes of application in different cell types15. For 
instance, we could acutely deplete Rec8 in unmodified mouse oocytes15, an experiment that required 
complex genetics in the past22. We have also been able to deplete the intracellular signalling 
molecule NLRP3 in human primary macrophages, which has not been possible with nucleic acid-
based depletion techniques in the past15. Here, we describe (1) the design of Trim-Away 
experiments; (2) the selection and preparation of reagents for Trim-Away experiments; (3) the 
procedures for Trim-Away in mouse oocytes and pre-implantation embryos; (4) the procedures for 
Trim-Away in primary cells and cell lines; and propose (5) quality controls for Trim-Away experiments. 
We also highlight and give advice on critical steps in the procedure. 
 
Overview of the Procedure 
For a successful Trim-Away experiment, a specific antibody that targets an intracellular protein of 
interest must be delivered into cells that contain TRIM21. If the endogenous levels of TRIM21 are not 
sufficient for protein degradation, TRIM21 must also be introduced together with or before antibody 
delivery. In this Protocol, we outline different methods for introducing antibody and TRIM21 into 
cells and give advice on how to preselect specific antibodies for a successful Trim-Away experiment. 
A routine Trim-Away experiment involves the following three events (Fig. 1): 
1. Ensuring sufficient TRIM21 levels in target cells of interest: TRIM21 is widely expressed in 
different cell types23. Depending on the expression level of the target protein, endogenous 
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TRIM21 levels may be sufficient for Trim-Away15. But as TRIM21 is continuously degraded 
during a Trim-Away experiment and typically not expressed at high levels, the endogenous level 
may be insufficient for complete target protein degradation. Additional TRIM21 can be 
introduced in the form of a transgene (i.e. DNA), mRNA or protein. Using TRIM21-encoding 
DNA, we have transiently transfected cell lines or created stable lines with a TRIM21 expression 
cassette integrated into their genome15 (see also Box 3). Stable lines simplify the workflow in a 
Trim-Away experiment because only the delivery of the antibody is required for acute protein 
degradation. In certain cases, cells with low expression levels of TRIM21 have to be pre-
selected by fluorescence activated cell sorting (FACS), because high expression of TRIM21 can 
sometimes lead to the formation of protein aggregates, which are non-functional15. We have 
also used in vitro transcribed mRNAs to transiently express TRIM21 in mouse oocytes15. Using 
mRNAs accelerates the expression of TRIM21 and allows fine-tuning of the expression level, but 
translation rates may vary for cells at different cell cycle stages. TRIM21 can also be introduced 
in the form of a recombinant protein, for instance by electroporation15. Recombinant TRIM21 
(see also Box 4) eliminates the incubation time that is required for protein expression from DNA 
or mRNA before a Trim-Away experiment. However, recombinant TRIM21 can be exhausted if 
not replenished.  
2. Delivery of antibody: Depending on the experimental setup, the antibody can be delivered by 
either microinjection (step 16) or electroporation (step 17 – 32). We have microinjected 
antibody into mouse oocytes and single adherent cells15. Microinjection allows tight control 
over the amount of antibody delivered into each cell, and is the method of choice when 
individual cells need to be analysed rapidly upon triggering protein degradation. For bulk cell 
populations, we recommend delivering the antibody by electroporation using the Neon 
Transfection System15. Unlike protein transfection reagents, electroporation can be used to 
simultaneously deliver the antibody into the cytoplasm of many cells without antibody 
accumulation in the endosome and/or lysosome. In addition to conventional antibodies, we 
have also used a fusion between a nanobody and the Fc-region of human IgG1 for protein 
degradation by Trim-Away15. We have introduced this nanobody-Fc fusion into mouse oocytes 
as mRNA, but delivery as DNA or protein into other cell types should work as well15. 
3. Target protein degradation: When the antibody has bound to the target protein, TRIM21 
targets the antibody-antigen complex for degradation via the ubiquitin-proteasome 
pathway20,21. Degradation typically starts within 5 – 10 minutes after application of the 
antibody15. Complete depletion can be achieved within ~3 hours, depending on the abundance 
and accessibility of the target protein, as well as the amount of antibody that was introduced 
into the cell15. 
 
Applications of the method 
Trim-Away utilizes TRIM21 to degrade endogenous proteins that are bound to an antibody. Our 
results suggest that any protein within a cell that is accessible by antibody can be degraded by Trim-
Away. As TRIM21 proteins and antibodies are highly conserved amongst different mammalian 
species, Trim-Away works with a wide range of cells and antibodies24. Trim-Away acts very rapidly 
and does not require prior modification of the target protein. It also works in various cell types, 
including non-dividing primary cells. Trim-Away also allows loss-of-function studies in primary 
immune cells, which could not be studied efficiently with nucleic acid-based depletion methods in 
the past. 
Some specific examples of what can be studied are (1) the function of a protein within a defined cell 
cycle stage without affecting its potential other functions during the other cell cycle stages; (2) the 
roles of proteins for the maintenance of cellular structures, even if these proteins are essential for 
the formation of these structures; (3) the functions of the cytoplasmic pool of certain proteins; (4) 
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the functions of certain proteins with a particular post-translational modification; (5) the functions of 
specific isoforms of certain proteins; and (6) structure-function relationships in certain proteins by 
depletion followed by rescue with different mutants. 
 
Advantages and limitations of the method 
In comparison to other currently available protein depletion techniques, Trim-Away has several 
unique advantages. Firstly, Trim-Away acts directly at the protein level. It is therefore effective 
against long-lived proteins, and the development of phenotypes does not rely on inherent turnover 
of the target protein. Secondly, Trim-Away does not require modification of the genome. It therefore 
greatly facilitates loss-of-function studies in models where DNA- and RNA-based depletion methods 
are often ineffective, including non-dividing primary cells. Thirdly, Trim-Away is a protein-based 
depletion method, and can be used in primary immune cells which have active nucleic acid-sensing 
machineries. Fourth, TRIM21 is widely-expressed in most tissues. This means that it may often be 
possible to take advantage of endogenously produced protein and not rely on ectopic overexpression 
or introduction of recombinant protein. Fifth, TRIM21 does not have a cellular housekeeping 
function, in contrast to E3s like von Hippel–Landau (VHL) that are typically used in PROTAC 
applications31.  This means there is no competition for endogenous substrates and less likelihood 
that normal metabolism will be impacted. Lastly, Trim-Away utilizes off-the-shelf reagents for 
protein-targeting. Antibodies have been produced for almost all proteins and are widely 
commercially available.  
As with any technique, there are limitations for Trim-Away. One limitation is that Trim-Away depends 
on the intrinsic proteasome activity. Hence, the efficiency of Trim-Away may be compromised in 
certain cell types and/or at certain cell cycle stages accordingly. As Trim-Away is a protein-targeting 
method, another limitation is that it is more challenging to evaluate off-targets when compared to 
gene- or mRNA-targeting methods. Thus, antibodies used for protein-targeting have to be carefully 
selected and validated before use, as discussed in the Experimental Design section (Antibody 
selection). In addition, antigen buried within the native protein or target stably localized in a 
particular cellular compartment such as the nucleus will not be accessible for degradation by the 
antibody. But the latter case may be circumvented by the use of the smaller nanobody-Fc fusion15. 
Finally, the usefulness of Trim-Away may be limited in certain models such as intact tissues, where it 
is challenging to deliver antibody by microinjection or electroporation. However, as there are 
intensive efforts to develop cell delivery reagents, it may become possible in the future to utilize 
Trim-Away even in intact tissue applications.  An important potential limitation in Trim-Away is that 
TRIM21 both targets proteins for degradation and can activate innate immune signal transduction 
pathways like NF-κB32. This is because TRIM21 synthesises K63-ubiquitin chains, which when 
released by the proteasomal DUB RPN11 acts as an immune second messenger21. Fortunately, there 
is a high activation barrier for TRIM21-signalling, and NF-κB activation is highly sensitive to changes 
in antibody affinity, concentration and viral dose33,34. For instance, in our Trim-Away experiment 
targeting IκBα for degradation, NF-κB was only weakly activated in control cells where mTOR was 
depleted15. If activation of NF-κB is a concern during Trim-Away, this can be assayed for either 
through the use of an NF-κB-luciferase reporter or by qPCR for cytokine transcripts. 
 
Experimental design 
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Antibody selection Similar to other antibody-based techniques, the specificity of the antibody is 
crucial for a successful Trim-Away experiment. A good antibody should degrade all antigens bearing 
the targeted epitope (i.e. on-target), but not irrelevant antigens (i.e. off-target). When selecting an 
antibody for Trim-Away, several parameters should be considered: 
 Antibody species: The TRIM21-antibody interaction is highly conserved and maintained both 
within and between murine, canine, primate and human species24. Our preliminary results with 
anti-GFP antibodies raised in mouse, rabbit and goat suggest no significance difference in their 
Trim-Away efficiency at the same concentration. We have also successfully used antibodies 
raised in rat15 . However, antibodies from less common hosts such as guinea pig and sheep 
should be tested before actual application. TRIM21 does not bind to chicken antibodies. 
 Isotype of antibody: TRIM21 has the highest affinity to IgG, followed by IgM and IgA25. Binding 
of TRIM21 to IgD or IgE remains unknown. TRIM21 does not bind IgY. 
 Form of antibody: Commercial antibodies are offered in different forms such as full length Ig, 
Fab and Fab2. As TRIM21 binds to the Fc-region of antibodies, Fab and Fab2 should be avoided. 
Considering the growing supply of nanobodies, we have also successfully used a fusion 
between a nanobody and the Fc-region of human IgG1 for Trim-Away experiments15. 
 Clonality of antibody: We have had success with both polyclonal and monoclonal antibodies. 
Because of lot variation between polyclonal antibodies, we recommend the use of monoclonal 
antibodies as they may yield better reproducible results. 
 Antigen of antibody: The epitope should be accessible for the antibody under native conditions. 
 Antibodies against post-translationally modified proteins: Our preliminary results suggest that 
Trim-Away can also be used to selectively degrade proteins with post-translational 
modifications, as long as specific antibodies are available. However, these antibodies need to 
be evaluated particularly carefully before usage. For instance, we observed non-specific binding 
of some polyclonal antibodies against phosphorylated kinetochore proteins to acentricolar 
microtubule organizing centres, which are also enriched in phosphorylated proteins in mouse 
oocytes (and the other way round). 
 
Antibody validation Before proceeding to Trim-Away, we generally validate the antibody by at least 
two of the experiments listed below: 
 Co-localisation with the fluorescently tagged protein: Most proteins localize correctly when they 
are tagged with a fluorescent protein. To evaluate if an antibody is specific, we compare the 
localization of the fluorescent protein with the pattern obtained by immunofluorescence using 
the antibody of interest. They should be identical. Exceptions to this are some long-lived 
proteins such as Rec8 and CenpA in mouse oocytes22,26. These proteins are only loaded 
correctly during particular stages of development, which do not allow further incorporation or 
displacement by their fluorescent reporter afterward. Also, comparison of the staining pattern 
with published data from other cell types is a useful way to test for specificity. 
 Antibody delivery followed by immunofluorescence: To determine the ability of antibody to 
recognize the target protein in live cells, we deliver the antibody by either microinjection or 
electroporation, fix and stain with a secondary antibody. The delivered antibody should show 
the same localization pattern as immunofluorescence of the target protein using a different 
antibody. It is also possible to fluorescently label the antibody in order to observe correct 
binding to target protein in live cells27. However, in some cases antibody delivery may cause 
target protein degradation via endogenous TRIM21 and/or cause target protein mislocalisation 
due to inhibitory effects of antibody binding. We therefore recommend traditional 
immunofluorescence as the preferred method to validate antibodies. 
 Immunoprecipitation followed by Western blotting: To determine the ability of antibody to 
recognize the target protein in native conformation in cells, we perform immunoprecipitation 
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on whole cell lysate in non-denaturing conditions. Specific antibody should enrich a single band 
corresponding to the target protein over background band(s) (if any) in Western blot. We do 
not recommend assessing the antibody by performing Western blotting alone, as that only 
provides information on the specific binding of antibody to the denatured epitope. 
 Cross-validation with other approaches: To test for specific binding of an antibody, when 
possible we first deplete the target protein with other approaches such as genome-editing or 
RNAi. This is followed by immunofluorescence using the antibody of interest. Specific binding of 
the antibody is confirmed by a reduction in the signal relative to the control. Such validation 
may also be provided by some antibody suppliers. 
 Peptide pre-incubation followed by immunofluorescence: To test for non-specific binding of an 
antibody, we pre-incubate the antibody with the immunizing peptide before 
immunofluorescence (Box 1). The degree of background binding can be estimated by the level 
of signal retained after blocking specific binding of the antibody. We highly recommend this 
assay for post translational modification-specific antibodies. 
 
Source of TRIM21 TRIM21 is widely-expressed in most tissues23. This means that most cell types will 
contain endogenous TRIM21 protein, and this may be sufficient for Trim-Away to work simply by 
delivering antibody to unmodified cells. Indeed, we have found that RPE-1 cells and primary 
macrophages contain sufficient endogenous TRIM21 for Trim-Away of several different target 
proteins15. Cell types can be screened for TRIM21 expression levels by RT-PCR or by western blotting 
using anti-TRIM21 antibodies (see Reagents section). Relative expression levels of TRIM21 can be 
compared to low expressing cells (HEK293T) or high expressing cells (RPE-1). As an initial Trim-Away 
experiment, we suggest delivering antibody to the cells of interest and screening for target protein 
depletion. Depending on the cell type and relative expression levels of cellular TRIM21 and target 
protein, antibody delivery alone may be sufficient for target protein depletion. If target protein 
depletion does not occur, or is incomplete, then methods for increasing cellular TRIM21 levels can be 
considered from the following options: 
 
 TRIM21 overexpression: In oocytes and early embryos we found it necessary to overexpress 
TRIM21 for successful Trim-Away. In these cell types microinjection of Trim21 mRNA is the 
recommended method. In bulk cell populations it is important to ensure that all cells in the 
population overexpress TRIM21. To achieve this we recommend generating stable cell lines as 
described in box 3. 
 Recombinant TRIM21 protein: For some cell types, particularly primary cells, it is not possible to 
generate stable cell lines overexpressing TRIM21. In this case it may be preferable to co-deliver 
recombinant TRIM21 protein together with antibody. Recombinant TRIM21 protein can be 
readily produced from bacteria as described in box 4. Bacterially-produced proteins may 
contain bacterial contaminants that could perturb certain cell types such as immune cells. In 
these cases it may be preferable to purify TRIM21 from insect or mammalian cells.  
 
 
Trim-Away by microinjection of oocytes and early embryos In our initial study, we microinjected 
Trim21 mRNA into arrested germinal vesicle (GV) oocytes, incubated the oocyte for expression and 
recovery for 3 hours, followed by microinjection of the antibody15. Depending on the biological 
questions to be addressed, antibodies can be microinjected immediately before meiotic release or 
during meiosis. While sequential injections can be mastered by scientists with extensive experience 
in micromanipulation, a significant reduction in oocyte survival and developmental rates is 
frequently observed for less experienced operators. 
We have therefore developed a simplified protocol that involves single microinjection, which 
minimizes harm to the cells. We here present protocols for both hydraulic- and pressure-based 
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microinjection systems. Hydraulic-based systems allow injection of a defined volume, but require the 
use of mercury-filled needles28. While it is challenging to consistently inject a defined volume using 
pressure-based systems, these systems are more widely available, do not involve mercury and allow 
more rapid microinjections. The new protocols offer several benefits. Firstly, single microinjection 
improves survival and developmental rates to levels comparable to routine live imaging experiments. 
Secondly, depletion starts immediately after microinjection as Trim21 mRNA is translated, which can 
be advantageous for early embryos that cannot be arrested at a particular stage of development. 
Lastly, target proteins that are expressed at high endogenous levels (which can take up to 3 – 4 hours 
for full depletion) are more completely degraded before meiotic release, and phenotypes during 
early meiosis are more consistent between individual oocytes. 
In addition, we optimized our protocol for preparing mRNAs encoding Trim21 and reporters for live-
cell imaging with several modifications. Firstly, the use of anti-reverse cap analog (ARCA) yields 
transcripts that are all capped in the correct orientation at the 5’ end and hence, a higher translation 
efficiency than mRNAs that have been synthesised with standard cap analog. Secondly, the increased 
ratio of cap analog and GTP relative to other NTPs enables the synthesis of transcripts of up to 12 kb 
at high yield. Lastly, the incorporation of a column clean-up step removes all free nucleotides, 
allowing higher accuracy in determination of mRNA concentration and reproducibility in expression 
level. 
 
Trim-away by electroporation of primary cells and cell lines A successful Trim-Away experiment in 
bulk cell populations depends on efficient delivery of antibody all the cells in a population. 
Antibodies are large molecules of ~150 kDa that cannot cross cell membranes. We initially tested 
antibody delivery by conventional chemical- and lipid-based transfection reagents in addition to 
several different commercially available protein and antibody transfection reagents. However, this 
most often led to antibodies being trapped inside intracellular vesicles with very little antibody 
actually reaching the cytosol. We also tested classical electroporation using conventional cuvettes. 
However, this caused high levels of cell death, and surviving cells tended to have morphologically 
changes and exhibited antibodies stuck to the cell surface, trapped inside intracellular vesicles and 
aggregated inside the cells. We and others have found that a new type of electroporation device with 
a capillary electrode15,27,29,30, available commercially as the Neon Transfection System, can be used to 
deliver antibodies directly to the cytoplasm of almost 100% of cells without cell death. Cells are 
morphologically normal following electroporation with the Neon system, and re-adhere and 
proliferate at a similar rate as non-electroporated cells15. Thus, Trim-Away experiments can be 
performed by electroporation of antibodies and phenotypes can be analysed as soon as the target 
protein is depleted, which is usually within 3 hours. In addition, we found efficient antibody delivery 
can also be achieved in primary cells such as normal human lung fibroblasts, mouse bone-marrow-
derived macrophages and human monocyte-derived macrophages15.  Here we include an optimized 
antibody electroporation protocol that we found to be suitable for antibody delivery in all cell types 
tested so far. 
 
Trim-Away controls To properly interpret a Trim-Away experiment certain controls can be included. 
To control for antibody delivery, we recommend using isotype control antibodies of the same 
clonality as the antibodies used for targeted protein degradation. Control antibodies are often raised 
against proteins that are not normally expressed in mammalian cells, such as GFP or yeast proteins, 
and are readily available from most antibody suppliers. Additional controls such as delivery of 
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antibody buffer alone and non-electroporated/microinjected cells can also be included.  If a Trim-
Away experiment requires TRIM21 overexpression, we also recommend including non-
overexpressing cells as an additional control. Importantly, we found that both antibody delivery and 
TRIM21 overexpression did not perturb cell proliferation or induce major changes in global transcript 
levels15.  
 
Confirmation of protein depletion by Trim-Away Confirmation of protein depletion by Trim-Away 
can be achieved by standard methods used to detect cellular levels of endogenous proteins. For 
example immunofluorescence, flow-cytometry or western blotting methods are suitable. When using 
indirect antibody-based detection methods to detect cellular levels of target proteins following Trim-
Away (and also other non-targeted cellular proteins), it is important to take into account that 
secondary antibodies will also detect residual electroporated/microinjected antibody present in the 
cell if the secondary antibodies are raised against the same species of antibody as the delivered 
antibody. This problem will arise if the antibody delivered to cells for Trim-Away is also used as a 
primary antibody for protein detection. When western blotting, this will result in detection of IgG 
heavy chain and light chain on the membrane (at ~50 kDa and ~25 kDa respectively), which may 
interfere with detection of endogenous proteins. When performing immunofluorescence or flow 
cytometry, this will result in higher levels of background signal. In all detection methods, this 
problem can be avoided by using primary antibodies of a different species to the antibodies 
delivered to the cells for Trim-Away. If there is no option but to use the same antibody (or antibodies 
from the same species) for Trim-Away and for detection, HRP-conjugated secondary antibodies that 
only bind to the native non-denatured IgG can be used for western blotting, and primary antibodies 
can be directly labelled with fluorophores for immunofluorescence and flow cytometry.	 
 
Confirmation of specificity in a Trim-Away experiment The specificity of depletion in a Trim-Away 
experiment is determined by the specificity of the antibody used. Thus antibodies should be selected 
carefully as described above (see Antibody selection).  If multiple antibodies raised against different 
regions of the same target protein are available, these can be used to confirm the specificity of a 
Trim-Away phenotype. Rescue experiments can also be performed by overexpressing exogenous 
target protein. When performing rescue experiments, it should be taken into account that the 
antibody delivered during Trim-Away will likely also target the exogenous protein for degradation. In 
this case it may be necessary to increase expression levels of the exogenous protein in order to 
saturate cellular antibody and TRIM21 to allow for a rescue. Similarly, the amount of delivered 
antibody should be used at a minimum to aid rescue experiments. It may also be possible to rescue a 
phenotype by overexpressing exogenous protein from a different species that is not recognised by 
the antibody used for Trim-Away. Another way to confirm the specificity of depletion is to express a 
fluorescently tagged target protein. Upon acute delivery of the antibody against the target protein, 
the fluorescent signal should be reduced as a result of co-degradation of the fluorescent tag. 
 
Materials 
Reagents 
 
Antibody preparation 
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 NAb protein A/G spin kit (0.2 ml; Thermo Scientific, cat. no. 89950) 
 Water (for embryo transfer; Sigma-Aldrich, cat. no. W1503) 
 Phosphate-buffered saline (PBS) tablets (Gibco, cat. no. 18912) 
 
Isolation and culture of mouse oocytes and pre-implantation embryos 
 Culture medium such as M2 medium (homemade or Sigma-Aldrich, cat. no. MR-015P) 
 NaCl (Sigma-Aldrich, cat. no. S5886) 
 KCl (Sigma-Aldrich, cat. no. P5405) 
 CaCl2•2H2O (Sigma-Aldrich, cat. no. C7902) 
 KH2PO4 (Sigma-Aldrich, cat. no. P5655) 
 MgSO4•7H2O (Sigma-Aldrich, cat. no. 63138) 
 NaHCO3 (Sigma-Aldrich, cat. no. S3817) 
 HEPES (Gibco, cat. no. 15630) 
 Na lactate (Sigma-Aldrich, cat. no. L7900) 
 Na pyruvate (Sigma-Aldrich, cat. no. 11360) 
 Glucose monohydrate (Sigma-Aldrich, cat. no. 49158) 
 Penicillin G (Sigma-Aldrich, cat. no. P3032) 
 Streptomycin (Sigma-Aldrich, cat. no. S9137) 
 Bovine serum albumin (BSA) (Sigma-Aldrich, cat. no. A3311) 
 Phenol red (Sigma-Aldrich, cat. no. P3532) 
 Oil (mineral; Sigma-Aldrich, cat. no. M5310 or paraffin; Merck Millipore, cat. no. 107174) 
 Mice ! CAUTION Animal experiments must be carried out according to institutional and national 
regulations. All experiments in this Procedure involving live mice were approved by the MRC 
Cambridge Ethical Review Committee and the UK Home Office under project license numbers 
PPL 70/8087 and PPL PCF3F9520. 
 
Constitutive Trim-Away in mouse oocytes and pre-implantation embryos 
 Hydrochloric acid (36.5 – 38.0% (vol/vol); Sigma-Aldrich, cat. no. H1758) 
 Silicon grease Bayer (medium vacuum; Sigma-Aldrich, cat. no. 85402) 
 Sigmacote (Sigma-Aldrich, cat. no. SL2) 
 Mercury (Sigma-Aldrich, cat. no. 261017) 
 NP-40 Surfact-Amps detergent solution (Thermo Scientific, cat. no. 28324) 
 Dimethylpolysiloxane (20 cSt; Sigma-Aldrich, cat. no. DMPS2X or 50 cSt; Sigma-Aldrich, cat. no. 
DMPS5X) 
 
Trim-Away by electroporation in cell lines and primary cells 
 DMEM (high glucose; GlutaMAX Supplement; pyruvate; Gibco, cat. no. 31966) 
 Fetal bovine serum (Gibco, cat. no. 10270) 
 DPBS (no calcium; no magnesium; Gibco, cat. no. 14190) 
 Trypsin-EDTA (0.05%; phenol red; Gibco, cat. no. 25300) 
 Cell lines of interest: We have used 293 [HEK-293] (ATCC, cat. no. CRL-1573), NIH/3T3 (ATCC, 
cat. no. CRL-1658), hTERT RPE-1 (ATCC, cat. no. CRL-4000), U-2 OS (ATCC, cat. no. HTB-96), HCT 
116 (ATCC, cat. no. CCL-247) and HeLa (ATCC, cat. no. CCL-2) cells, although any mammalian cell 
line may be used. Cell lines should be grown in the appropriate growth media and maintained 
by standard cell culture methods. ! CAUTION Cell lines should be regularly checked to ensure 
they are authentic and not infected with mycoplasma. 
 Primary cells of interest: We have used NHLF (Lonza, cat. no. CC2512), human monocyte-
derived macrophages and mouse bone-marrow-derived macrophages, although any 
mammalian primary cells may be used. 
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 Mouse anti-TRIM21 (D-12; Santa Cruz Biotechnology, cat. no. sc-25351) 
 Rabbit anti-TRIM21 (D1O1D; Cell Signalling Technology, cat. no. 92043S) 
 
Equipment 
 
Antibody preparation 
 Amicon Ultra-0.5 centrifugal filter unit with Ultracel-100 membrane (Merck Millipore, cat. no. 
UFC100) 
 
Isolation and culture of mouse oocytes and pre-implantation embryos 
 TC-treated easy-grip style cell culture dish (35 mm; Corning, cat. no. 353001) 
 Microcapillary tube (100 µl; Sigma-Aldrich, cat. no. P1174) 
 Aspirator tube assemblies for calibrated microcapillary pipettes (Sigma-Aldrich, cat. no. A5177) 
 Stereomicroscope (Zeiss, cat. no. SteREO Discovery.V8) 
 Galaxy 48 R (Eppendorf, cat. no. CO482) 
 
Constitutive Trim-Away in mouse oocytes and pre-implantation embryos 
 Inverted microscope (Zeiss, cat. no. Axio Vert.A1) 
 Crossline micrometer (Zeiss, cat. no. 474066-9901-000) 
 Vibration-free table (Gutmann, cat. no 14.860) 
 Stage micrometer for transmitted light (Zeiss, cat. no. 474026-0000-000) 
 Coarse manipulator (Narishige, cat. no. MN-4) 
 Three-axis joystick oil hydraulic micromanipulator (Narishige, cat. no. MO-202U) 
 Adapter Zeiss 2 (for Eppendorf micromanipulation systems; Eppendorf, cat. no. 5192312002) 
 TransferMan 4r (Eppendorf, cat. no. 5193000012) 
 22×22 mm #0 glass coverslips (Sigma-Aldrich, cat. no. C9802) 
 Diamond pencil (CellPath, cat. no. MEA-0301-00A) 
 Microinjection chamber (design adapted from ref. 28.) 
 Capillary that fits into the groove of the microinjection chamber (e.g. Drummond Scientific 
Company, cat. no. 1-00-0300) 
 Microcaps (Drummond Scientific Company, cat. no. 1-000-0500) 
 Flaming/Brown micropipette puller (Sutter Instrument, cat. no. P-97) 
 Calibrated syringe (10 µl; Hamilton, cat. no. 80300) 
 CellTram Oil (Eppendorf, cat. no. 5176000076) 
 Microloader (Eppendorf, cat. no. 5242956003) 
 Femtotip II (Eppendorf, cat. no. 5242957000) 
 FemtoJet 4i (Eppendorf, cat. no. 5252000013) 
 Holding capillary (VacuTip; Eppendorf, cat. no. 5175 108.000 or VacuTip FCH; Eppendorf, cat no. 
5175 240.006) 
 CellTram Air (Eppendorf, cat. no. 5176000068) 
 TC-treated easy-grip style cell culture dish (60 mm; Corning, cat. no. 353004) 
 
Trim-Away by electroporation in cell lines and primary cells 
 Corning tissue-culture treated culture dishes (100 mm × 20 mm; Sigma-Aldrich, cat. no. 
CLS430167) 
 Tube (15 ml; PP; screw cap; Greiner Bio-One, cat. no. 188285) 
12 
 
 Eppendorf Safe-Lock tubes (1.5 ml; Eppendorf, cat. no. 0030120086) 
 Neon Transfection System starter pack (Invitrogen, cat. no. MPK5000S) 
 
Reagent setup 
 
Trim21 and reporter mRNA mRNAs encoding Trim21 and reporters for live-cell imaging such as 
meGFP-MAP4 and H2B-mCherry are prepared by in vitro transcription as described in Box 2 and can 
be stored at -80oC as long as no signs of mRNA degradation can be seen . 
 
TRIM21-overexpressing stable cell lines TRIM21-overexpressing cell lines are prepared as described 
in Box 3 and can be cultivated at 37oC/5% CO2 as long as no signs of senescence can be seen. 
 
Recombinant TRIM21 protein.TRIM21 protein is prepared by purification from bacteria as described 
in Box 4 and can be stored at -80oC as long as no signs of protein degradation can be seen. 
 
PBS for antibody preparation. Dissolve 5 g of PBS tablet in 500 ml of embryo-tested or nuclease-free 
water. Store at room temperature as long as no signs of contamination can be seen. 
 
Homemade culture medium for isolating mouse oocytes and pre-implantation embryos. We 
routinely use modified M2 medium as described in ref. 35 for culture of mouse oocytes and pre-
implantation embryos. The modified M2 medium contains 5.53 g/l NaCl, 0.36 g/l, KCl, 0.25 g/l 
CaCl2•2H2O, 0.16 g/l KH2PO4, 0.29 g/l MgSO4•7H2O, 0.35 g/l NaHCO3, 4.97 g/l HEPES, 2.6 g/l Na 
lactate, 0.04 g/l Na pyruvate, 1.1 g/l glucose monohydrate, 4 g/l BSA, 0.06 g/l penicillin G, 0.05 g/l 
streptomycin and 0.002 g/l phenol red. We reduce the concentration of phenol red from 0.01 g/l to 
0.002 g/l as phenol red is toxic for mouse oocytes and early embryos. Store at 4oC for up to up to two 
weeks. 
Δ	 CRITICAL	 We obtain higher developmental rates with homemade M2 medium than with 
commercial M2 medium. 
Δ	CRITICAL	Drugs such as 250 μM dibutyryl cyclic adenosine monophosphate should be added to 
the culture medium to maintain meiotic arrest for GV oocytes.	
 
DMEM supplemented with 1X GlutaMAX and 10% (vol/vol) fetal bovine serum Add 55 ml of fetal 
bovine serum to 500 ml of DMEM. Store at 4oC until use. 
 
Equipment setup 
Mouth pipette for isolation and culture of mouse oocytes and pre-implantation embryos Pull 
microcapillary tubes above a gas burner. Break the tip by striking the pair of pipettes against each 
other to obtain a smooth opening of ~80 – 100 μm. Attach a pipette to the aspirator tube assembly. 
More details on mouth pipettes can be found in ref. 36. 
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Microinjection setup Install the inverted microscope on a vibration-free table. For the use of 
hydraulic-based systems, mount the coarse manipulator and the three-axis joystick oil hydraulic 
micromanipulator on one side of the arm. For the use of pressure-based systems, install the Adapter 
Zeiss 2 and mount a TransferMan 4r to both sides of the arm. 
 
Coverslips Boil 0.5 L of deionized water in a microwave oven, add a few drops of dishwashing 
detergent and add 22×22 mm #0 glass coverslips one-by-one. Incubate for 20 min at room 
temperature and discard the detergent solution. Rinse with deionized water thrice, boil and rinse 
with deionized water thrice again. Transfer the coverslips one-by-one to 0.5 L of 5 M hydrochloric 
acid and incubate overnight at room temperature. Rinse five times with deionized water and three 
times with double distilled water. Transfer the coverslips one-by-one to 70% (vol/vol) ethanol for 
storage. Blot-dry excess ethanol solution and air-dry before use. 
Δ	CRITICAL	Using	unwashed	coverslips	for	microinjection	may	compromise	the	survival	rate	of	
oocytes	and	early	embryos	during	microinjection.	
	
Microinjection chamber Cut a washed coverslip along the edges into 6 equal rectangular pieces 
(shelves) and a centre square piece with a diamond pencil. Attach a piece of double-sided tape of 
approximately the same dimension as a shelf (as a spacer of ~100 μm) close to the center of another 
washed coverslip at ~5 mm from one edge. Attach a shelf to the double-sided tape to form a ~0.5 
mm loading space at the side closest to the edge. Apply a thin layer of silicon grease along the U-
shape cut on both sides of the microinjection chamber. Attach the coverslip with the loading space 
facing away from the U-shape cut to the side of the microinjection chamber with a groove for placing 
the capillary. Attach another washed coverslip to the other side of the microinjection chamber. 
Gently press on the coverslips to spread the silicon grease. Fill the U-shaped reservoir with culture 
medium and keep the microinjection chamber in a humidified container at 37oC before use. After 
loading and before microinjection, apply a thin layer of silicon grease along the groove and insert the 
capillary with mRNA and/or antibody. 
 
Microinjection needle Siliconize microcaps by dipping one end in a beaker containing ~0.5 cm of 
Sigmacote. A column of Sigmacote will form due to capillary action. Invert microcaps end-to-end 
several times so that the entire length is fully covered with Sigmacote. Blot-dry excess Sigmacote at 
one end and air-dry for at least two weeks. Pull siliconized microcaps in a Flaming/Brown 
micropipette puller to obtain pairs of pipettes with an opening of ~0.5 – 1 μm after breaking the tip. 
Back-load ~1 µl of mercury as close to the tip as possible with a 10 µl calibrated syringe. 
Δ	 CRITICAL	 Siliconizing	 microcaps	 largely	 facilitate	 the	 flow	 of	 mercury	 within	 the	
microinjection	needle.	
Δ	 CRITICAL	 Insufficient	 drying	 of	 Sigmacote	 increases	 the	 chance	 of	 breaking	 the	 mercury	
column	during	microinjection.	
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CellTram Oil Set up the CellTram Oil according to the manufacturer’s instructions. Fill it with mineral 
oil. 
 
FemtoJet 4i Set up the FemtoJet 4i according to the manufacturer’s instructions. 
 
CellTram Air Set up the CellTram Air according to the manufacturer’s instructions. 
 
Neon Transfection System for electroporation in primary cells and cell lines The Neon Transfection 
System is setup according to manufacturer’s instructions. 
 
Procedure 
Antibody Preparation for Trim-Away (TIMING 1 – 2 hours) 
Δ	 CRITICAL	 This	 section	 describes	 how	 to	 prepare	 the	 antibody	 of	 interest	 for	 Trim-Away.	
Ultrafiltration	is	necessary	for	removing	contaminants,	which	are	cytotoxic	(e.g.	sodium	azide)	
or	interfere	with	microinjection	(e.g.	glycerol).	
1. If the antibody is from an unpurified source such as serum, ascites fluid and cell culture 
supernatant, or contains BSA or gelatin, pre-purify the antibody using the 0.2 ml Nab protein A/G 
spin kit. 
Δ	CRITICAL	STEP	This	step	is	necessary	for	removing	contaminating	proteins,	which	lead	to	an	
overestimation	 of	 the	 IgG	 concentration.	 Gelatin	 is	 not	 compatible	with	 the	 Amicon	 Ultra-0.5	
100K	devices	used	in	Step	3. 
2. Mix the components tabulated below in a 1.5 ml nuclease-free tube on ice. 
Component	 Amount	per	reaction	(µl) Final	concentration	
PBS	 (in	 embryo-tested	 or	
nuclease-free	water)	
400	– 450	
1	mg/ml	Antibody	 50	– 100	 0.1 – 0.2 µg/µl	
Δ	CRITICAL	STEP	For	co-injection	of	Trim21	mRNA	and	antibody	using	FemtoJet,	PBS	should	be	
prepared	in	nuclease-free	water	instead	to	reduce	the	chance	of	RNase	contamination. 
3. Insert an Amicon Ultra-0.5 100 K device into a provided collection tube. 
4. Apply 500 µl	of	diluted	antibody	from	step	2	to	the	device. 
5. Align	the	cap	strap	of	the	collection	tube	and	the	membrane	of	the	device	towards	the	center	
of	the	rotor. 
6. Centrifuge	at	14,000	×g	for	10	min	at	4oC. 
Δ	CRITICAL	STEP	Higher	centrifugal	force	may	damage	the	membrane	and	cause	sample	loss. 
7. Discard the flow-through. 
8. Add 480 µl	of	PBS	to	the	Amicon	Ultra-0.5	100	K	device	and	carefully	mix	well. 
Δ	 CRITICAL	 STEP	 Mixing	 is	 necessary	 for	 avoiding	 high	 local	 concentration	 during	
ultrafiltration,	which	can	cause	protein	aggregation	and	loss.	Avoid	touching	the	membrane	with	
the	pipette	tip	as	this	may	damage	the	membrane	and	cause	sample	loss. 
9. Repeat step 5-7 twice. 
? TROUBLESHOOTING 
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10. Insert the inverted Amicon Ultra-0.5 100 K device into another provided collection tube. 
11. Align the open cap towards the centre of the rotor. 
12. Centrifuge at 1,000 ×g	for	2	min	at	4oC. 
13. Use 2 µl	to	measure	the	IgG	concentration	with	a	NanoDrop	spectrophotometer.	
Δ	CRITICAL	STEP	1.0	OD280	is	equivalent	to	0.714	mg/ml	IgG.	
Δ	CRITICAL	STEP	We	typically	retrieve	~20	µl	of	purified	antibody	at	~1.25	–	2.5	mg/ml	from	
50	µg	of	input.	
? TROUBLESHOOTING 
14. Snap-freeze in liquid nitrogen. 
Δ	 CRITICAL	 STEP	 Purified	 antibody	 should	 be	 divided	 into	 1	 –	 2	 µl	 single-use	 aliquots	 to	
minimize	freeze-thaw	cycles	in	the	absence	of	cryoprotectant.		
	PAUSE	POINT	Antibody	can	be	stored	at	-80oC	as long as no loss of activity can be seen.	
 
Isolation and culture of mouse oocytes and pre-implantation embryos (TIMING >1 hour)  
15. Isolate and culture mouse GV, meiosis II (MII) oocytes or early embryos under oil as previously 
described in ref. 37 – 42. 
 
Trim-Away by microinjection of mouse oocytes and pre-implantation embryos (TIMING 4 – 
5 hours) 
16. To perform constitutive depletion (Fig. 3a) using hydraulic systems, follow option A. To perform 
constitutive depletion using pressure-based systems, follow option B. To perform acute depletion 
(Fig. 3b), follow option C. 
(A) Constitutive depletion using hydraulic-based systems such as CellTram Oil (TIMING 4 – 5 
hours) 
(i) Mix the components tabulated below in a 1.5 ml nuclease-free tube on ice. 
Component Amount	per	reaction	(µl) Final	concentration	
2	 µg/µl	 Trim21	
mRNA	
0.5 400	ng/µl
Reporter	mRNA(s)	 Variable Usually	 30	 –	 300	
ng/µl	each	
Nuclease-free	water	 To	2.5

	PAUSE	POINT	mRNA	mix	can	be	stored	at	-20oC	or	-80oC	until	use.	We	usually	freeze-
thaw	the	mRNA	mix	up	to	4	times	without	noticeable	RNA	degradation. 
(ii) Mix the components tabulated below in another 1.5 ml nuclease-free tube on ice. 
Component Amount	per	reaction	(µl) Final	concentration	
2	 mg/ml	 Antibody/	
antibodies	 from	
Step	14	
1.25 1	mg/ml each	
0.5%	 (vol/vol)	 NP-
40	 (in	 embryo-
tested	water)	
0.25	– 0.5 0.05	– 0.1% (vol/vol)	
PBS	 (in	 embryo-
tested	water)	
To	2.5
16 
 
Δ	CRITICAL	STEP	Antibody	at	a	final	concentration	of	1	mg/ml	is	a	good	starting	point	
for	complete	depletion	of	most	target	proteins.	However,	we	suggest	titrating	individual	
antibodies	to	the	minimal	effective	concentration,	as	some	can	have	secondary	inhibitory	
effects.	
Δ	CRITICAL	STEP	For	antibody	at	a	final	concentration	of	<0.1	mg/ml,	storage	in	a	low	
protein-binding	tube	or	preparation	of	fresh	antibody	mix	is	recommended.	
Δ	CRITICAL	STEP	NP-40	largely	facilitates	the	flow	of	the	viscous	antibody	mix	within	
the	microinjection	needle	and	reduces	the	chance	of	clogging.	
	PAUSE	POINT	For	short-term	storage	(up	to	1	week),	antibody	mix	can	be	stored	at	
4oC	 in	a	1.5	ml	 tube	with	 the	opening	sealed	with	Parafilm.	However,	 changes	 in	 ionic	
strength	 due	 to	 repeated	 evaporation	 and	 condensation	 at	 the	 cap	 can	 denature	 the	
antibody/antibodies.	For	 long-term	storage	 (up	 to	at	 least	1	month),	 the	antibody	mix	
can	be	stored	at	-20oC	or	-80oC	until	use.	We	usually	freeze-thaw	the	antibody	mix	up	to	
4	times	without	noticeable	loss	of	activity.	
(iii) Centrifuge the mRNA mix and antibody mix at 20,000 ×g	 for	 5	 min	 at	 4oC	 before	
capillary	loading. 
Δ	 CRITICAL	 STEP	 This	 step	 is	 necessary	 for	 reducing	 the	 amount	 of	 precipitated	
materials	loaded	into	the	capillary. 
(iv) Load 0.5 µl	of	dimethylpolysiloxane	into	a	capillary. 
Δ	CRITICAL	STEP	Avoid	introducing	air	bubbles	from	step	16(A)(iv)	to	(viii).	
Δ	CRITICAL	STEP	Follow	the	order	of	loading	(Fig.	3c)	from	step	16(A)(iv)	to	(viii). 
(v) Load	0.5	µl	of	pre-cleared	antibody	mix. 
Δ	CRITICAL	STEP	Down	to	0.25	µl	can	be	used. 
(vi) Load 0.5 µl	of	dimethylpolysiloxane. 
(vii) Load	0.5	µl	of	pre-cleared	mRNA	mix. 
Δ	CRITICAL	STEP	Down	to	0.25	µl	can	be	used. 
(viii) Load 0.5 µl	of	dimethylpolysiloxane. 
? TROUBLESHOOTING 
Δ	CRITICAL	STEP	Loaded	capillary	should	be	kept	on	ice	until	use.	
(ix) Transfer oocytes or early embryos into the loading space of the microinjection 
chamber using a mouth pipette under the stereomicroscope. 
(x) Mount a microinjection needle onto the capillary holder attached to the CellTram 
Oil. 
(xi) Attach the capillary holder to the micromanipulator. 
(xii) Carefully tap the tip of the microinjection needle against the wall of the capillary to 
obtain an opening of ~0.5 – 1 μm	 and	 slowly	 push	 the	 mercury	 column	 to	 the	
front. 
Δ	 CRITICAL	 STEP	 An	 opening	 of	 >1	 μm	 will	 increase	 the	 risk	 of	 lysis	 after	
microinjection,	but	an	opening	of	<0.5	μm	will	increase	the	chance	of	clogging.	
(xiii) Determine the injection volume by loading different amount of polydimethylsiloxane 
into the microinjection needle and carefully expelling into the mRNA mix. A 
polydimethylsiloxane droplet will form. The corresponding volume can be calculated 
using the formula 4/3 × π × (d/2)3, where d is the diameter of the droplet. 
(xiv) Load ~1 pl of polydimethylsiloxane	into	the	microinjection	needle. 
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(xv) Load	3.5	pl	of	mRNA	mix. 
(xvi) Load	~1	pl	of	polydimethylsiloxane. 
(xvii) Load	3.5	pl	of	antibody	mix. 
(xviii) Load	~1	pl	of	polydimethylsiloxane. 
Δ	 CRITICAL	 STEP	 mRNA	 mix	 and	 antibody	 mix	 should	 not	 be	 mixed	 within	 the	
microinjection	needle	to	avoid	RNA	degradation	before	microinjection.	
Δ	CRITICAL	STEP	The	antibody	mix	can	be	injected	at	a	volume	of	up	to	8.5	pl	without	
harming	 the	 oocytes,	which	may	 be	 necessary	 for	 antibody/antibodies	 that	 cannot	 be	
concentrated	further	to	the	desired	concentration.	
(xix) Adjust	the	level	of	the	microinjection	needle	until	 it	 is	in	focus	with	the	plasma	
membrane	of	the	oocyte	or	early	embryo.	
(xx) Carefully	 press	 the	 tip	of	 the	microinjection	needle	 against	 the	 oocyte	 or	 early	
embryo	until	it	penetrates	the	plasma	membrane.	
(xxi) Expel	 the	 column	 of	 polydimethylsiloxane-mRNA	 mix-polydimethylsiloxane-
antibody	mix	into	the	cytoplasm.	
(xxii) Quickly	 withdraw	 the	 microinjection	 needle	 to	 release	 the	 oocyte	 or	 early	
embryo.	
(xxiii) Repeat	step	(xiv)-(xxii).	
	
Δ	CRITICAL	STEP	A	successful	microinjection	is	 indicated	by	a	cytoplasmic	movement	
and	the	presence	of	two	dimethylpolysiloxane	droplets.	
Δ	CRITICAL	STEP	A	video	and	an	illustration	describing	hydraulic-based	microinjection	
step-by-step	 can	 be	 found	 at	 https://health.uconn.edu/cell-biology/wp-
content/uploads/sites/115/2017/07/follicleinjection.mp4?_=2	 and	 in	 ref.	 42,	
respectively.	
? TROUBLESHOOTING 
(xxiv) Transfer	 microinjected	 oocytes	 or	 early	 embryos	 from	 the	 microinjection	
chamber	to	a	50	µl	drop	of	culture	medium	covered	with	oil	in	a	35	mm	dish.	
(xxv) Incubate	 at	 37oC	 for	 3	 hr	 before	 performing	 an	 assay	 such	 as	 live	 imaging	 or	
immunofluorescence.	
Δ	CRITICAL	STEP	Full	depletion	of	some	target	proteins	can	take	up	to	4	hr.	
? TROUBLESHOOTING 
(B) Constitutive depletion using pressure-based systems such as FemtoJet 4i (TIMING 4 – 5 
hours) 
(i) Mix the components tabulated below in a 1.5 ml nuclease-free tube on ice. 
Component Amount	per	reaction	(µl) Final	concentration	
2	 µg/µl	 Trim21	
mRNA	
0.25 200	ng/µl
Reporter	mRNA(s)	 Variable Usually	 15	 –	 150	
ng/µl	each	
2	 mg/ml	 Antibody/	
antibodies	 from	
Step	14	
0.625 0.5	mg/ml each	
0.5%	 (vol/vol)	 NP-
40	 (in	 nuclease-free	
water)	
0.25	– 0.5 0.05	– 0.1%	(vol/vol)	
PBS	 (in	 nuclease-
free	water)	
To	2.5
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Δ	CRITICAL	STEP	Antibody	at	a	final	concentration	of	0.5	mg/ml	is	a	good	starting	point	
for	complete	depletion	of	most	target	proteins.	However,	we	suggest	titrating	individual	
antibodies	to	the	minimal	effective	concentration,	as	some	can	have	secondary	inhibitory	
effects.	
Δ	CRITICAL	STEP	For	antibody	at	a	final	concentration	of	<0.1	mg/ml,	storage	in	a	low	
protein-binding	tube	or	preparation	of	fresh	mRNA	&	antibody	mix	is	recommended.	
Δ	CRITICAL	STEP	NP-40	 largely	 facilitates	 the	 flow	 of	 viscous	mRNA	&	 antibody	mix	
within	the	Femtotip	II	and	reduces	the	chance	of	clogging.	
	PAUSE	POINT	The	mRNA	and	antibody	mix	can	be	stored	at	-20oC	or	-80oC	until	use.	
We	 usually	 freeze-thaw	 the	 mRNA	 &	 antibody	 mix	 up	 to	 4	 times	 without	 noticeable	
denaturation	and/or	RNA	degradation.	
(ii) Centrifuge the mRNA and antibody mix at 20,000 ×g	 for	 5	 min	 at	 4oC	 before	
loading.	
Δ	 CRITICAL	 STEP	 This	 step	 is	 necessary	 for	 reducing	 the	 amount	 of	 precipitated	
materials	loaded	into	the	capillary. 
(iii) Load 0.5 µl	 of	 mRNA	 and	 antibody	 mix	 to	 the	 tip	 of	 a	 Femtotip	 II	 using	
Microloader. 
Δ	CRITICAL	STEP	Avoid	introducing	air	bubbles. 
(iv) Mount a Femtotip II onto the capillary holder of the FemtoJet 4i. 
(v) Mount a holding capillary onto the capillary holder of the CellTram Air. 
Δ	CRITICAL	STEP	We	have	also	successfully	used	the	FemtoJet	4i	with	a	microinjection	
chamber	instead	of	a	holding	capillary. 
(vi) Attach the capillary holders to TransferMan 4r. 
(vii) Transfer oocytes or early embryos to a drop of culture medium covered with oil on 
the lid of a 60 mm dish. 
(viii) Determine the appropriate settings for the microinjection program to inject a 
volume of ~7 pl by first microinjecting different amount of a fluorescent dye into 
oocytes or early embryos and measuring the intracellular fluorescence intensity and 
the fluorescence intensity of a series of dye solutions of known concentration. The 
injection volume can then be calculated using the formula Fdye injected × Vdye injected = Fcell 
× Vcell, where Fdye injected and Vdye injected is the fluorescence intensity and volume of the 
dye solution microinjected, and Fcell and Vcell is the fluorescence intensity and volume 
of the oocyte or early embryo microinjected. More details can be found in ref. 43 
and 44. 
Δ	 CRITICAL	 STEP	 This	 step	 depends	 on	 the	 experience	 of	 the	 scientist	 and	 may	 be	
optional.	
Δ	CRITICAL	STEP	The	mRNA	and	antibody	mix	can	be	injected	at	a	volume	of	up	to	12	pl	
without	 harming	 the	 oocytes,	 which	 may	 be	 necessary	 for	 antibody/antibodies	 that	
cannot	be	concentrated	further	to	the	desired	concentration.	
(ix) Adjust the level of the holding capillary until it is in focus with the oocyte or early 
embryo. 
(x) Secure an oocyte or early embryo in place by applying a negative pressure at the 
holding capillary. 
(xi) Adjust the level of the Femtotip II until it is in focus with the plasma membrane of 
the oocyte or early embryo. 
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(xii) Push the tip of the Femtotip II against the oocyte or early embryo until it penetrates 
the plasma membrane. 
(xiii) Press the ‘Inject’ button on the FemtoJet 4i to expel ~7 pl of mRNA and antibody mix 
into the cytoplasm. 
(xiv) Quickly	withdraw	the	microinjection	needle.	
(xv) 	Release	 the	 oocyte	 or	 early	 embryo	 by	 applying	 a	 positive	 pressure	 at	 the	
holding	capillary.	
(xvi) Repeat	step	(ix)	to	(xv).	
Δ	CRITICAL	STEP	A	successful	microinjection	is	indicated	by	a	cytoplasmic	movement.	
Δ	CRITICAL	STEP	A	video	describing	pressure-based	microinjection	step-by-step	can	be	
found	in	ref.	45.	
? TROUBLESHOOTING 
(xvii) Transfer	microinjected	oocytes	or	early	embryos	from	the	stage	to	a	50	µl	drop	of	
culture	medium	covered	with	oil	in	a	35	mm	dish.	
(xviii) Incubate	 at	 37oC	 for	 3	 hr	 before	 performing	 an	 assay	 such	 as	 live	 imaging	 or	
immunofluorescence.	
Δ	CRITICAL	STEP	Full	depletion	of	some	target	proteins	can	take	up	to	4	hr.	
? TROUBLESHOOTING 
(C) Acute depletion (TIMING >4 hours) 
(i) Prepare	the	mRNA	mix	as	in	step	16(A)(i).	
(ii) Microinject	3.5	pl	using	a	hydraulic-based	system	as	in	step	16(A)(iii)-(xix)	or	a	
pressure-based	system	as	in	step	16(B)(ii)-(ix)	
(iii) Transfer	microinjected	 oocytes	 or	 early	 embryos	 to	 a	 drop	 of	 culture	medium	
covered	with	oil.	
(iv) Incubate	at	37oC	until	the	desired	developmental	stage.	
(v) Prepare	the	antibody	mix	as	in	step	16(A)(ii).	
(vi) Repeat	step	16(C)(ii).	
(vii) Immediately	proceed	to	assay	such	as	live	imaging	or	immunofluorescence.	
 
Trim-Away by electroporation in primary cells and cell lines (TIMING <1 hour) 
17. Trypsinise the cells using standard cell culture procedure and transfer to a 15 ml tube. 
18. Pellet the cells at 300 xg for 5 minutes at room temperature and discard the supernatant. 
19. Resuspend the cell pellet in 10 ml of PBS and count the cells. 
Δ	CRITICAL	STEP	The	cells	should	be	thoroughly	resuspended	in	PBS	to	avoid	cell	clumping	
that	can	give	inaccurate	results	in	cell	counting	
	
20. Transfer n x (8 x 105) cells to a new 15 ml tube (where n = number of electroporation reactions) 
Δ	CRITICAL	STEP	We	routinely	use	8	x	105	cells	per	electroporation	reaction	using	a	10	µl	
Neon	tip.	However,	 it	 is	possible	 to	use	any	number	of	cells	between	1	x	105	and	1.5	x	106	
depending	on	the	type	and	size	of	cells,	without	any	detrimental	effects	on	antibody	delivery	
or	cell	survival.	
	
21. Pellet the cells at 300 xg for 5 min at room temperature and discard all but ~1 ml of supernatant. 
22. Using residual supernatant, transfer the cells to a new 1.5 ml tube. 
23. Pellet the cells at 300 xg for 5 min at room temperature. In the meantime, proceed with Step 24. 
24. During step 23, insert a Neon Tube into the Neon Pipette Station and fill the Neon Tube with 3 ml 
of Neon Buffer E. 
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25. Carefully remove the supernatant. 
Δ	CRITICAL	STEP	Supernatant	should	be	removed	carefully	using	a	Gilson	pipette	to	avoid	
disturbing	the	cell	pellet	and	subsequent	cell	loss.		
	
26. Resuspend the cell pellet in n x 10 µl of Neon Buffer R (where n = number of electroporation 
reactions). 
Δ	 CRITICAL	 STEP	 Once	 the	 cells	 are	 resuspended	 in	 Neon	 Buffer	 R,	 it	 is	 important	 to	
proceed	with	electroporation	immediately.	Prolonged	incubation	(>30	min)	in	Neon	Buffer	R	
can	reduce	cell	viability.	
	
27. Aliquot 10.5 µl (~8 x 105) of cells per electroporation reaction into 1.5 ml tubes. 
Δ	CRITICAL	STEP	 It	 is	 important	 to	 avoid	 introducing	 air	 bubbles	 that	 can	 cause	 arcing	
during	electroporation	 
 
28. Add 2 µl of antibody from Step 14 to the cells and mix gently. 
Δ	 CRITICAL	 STEP	 Antibody	 at	 a	 concentration	 of	 1	 mg/ml	 is	 a	 good	 starting	 point	 for	
complete	 depletion	 of	 most	 target	 proteins.	 However,	 we	 suggest	 titrating	 individual	
antibodies	 to	 the	minimal	 effective	 concentration,	 as	 some	 can	 have	 secondary	 inhibitory	
effects.	
Δ	CRITICAL	STEP	 It	 is	 important	 to	 avoid	 introducing	 air	 bubbles	 that	 can	 cause	 arcing	
during	 electroporation.	 Gently	 tapping	 the	 tube	 can	 help	 remove	 any	 air	 bubbles.	 A	 total	
volume	of	12.5	µl	per	electroporation	reaction	should	be	used	as	this	helps	prevent	that	any	
air	bubbles	are	taken	up	into	the	Neon	10	µl	Tip	in	step	28.	
 
29. Take up the cell/antibody mix into the Neon 10 µl Tip. 
Δ	CRITICAL	STEP	It	is	essential	to	avoid	taking	up	air	bubbles	into	the	Neon	10	µl	Tip	that	
can	cause	arcing	during	electroporation.	Use	a	single	smooth	pipetting	action	combined	with	
gentle	swirling	is	recommended.	Avoid	pipetting	up	and	down.	For	detailed	instructions	on	
how	to	insert	the	Neon	10	µl	Tip	into	the	Neon	Pipette	refer	to	the	Neon	Transfection	System	
manual. 
 
? TROUBLESHOOTING 
 
30. Insert the Neon Pipette with the sample in the tip into the Neon Tube containing 3 ml of Neon 
Buffer E assembled in the Neon Pipette Station. Push	down	vertically	until	a	‘click’	is	heard. 
 
31. Electroporate using the following parameters: 1400 V, 2 pulses, 20 ms per pulse. 
Δ	CRITICAL	STEP	If	there	is	a	visible	spark,	discard	the	sample	and	return	to	step	28.	
 
32. Transfer the sample to a 1.5 ml tube containing 1 ml of pre-warmed cell growth media without 
antibiotics. Electroporated cells can now be plated as determined by the scientist. An incubation 
time of ~3 hours is usually sufficient for target protein degradation. 
 
? TROUBLESHOOTING 
 
Timing 
Step 1-14, Antibody preparation: 1 – 2 hours 
Step 15, Isolation and culture of mouse oocytes and pre-implantation embryos: >1 hour 
Step 16, Trim-Away by microinjection of mouse oocytes and pre-implantation embryos: 4 – 5 hours 
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Step 17-32, Trim-Away by electroporation in primary cells and cell lines: <1 hour 
 
Troubleshooting 
 
Step Problem Possible reason Solution 
Antibody preparation 
9 Antibody cannot be 
concentrated further to 
~20 µl. 
The membrane is 
clogged due to 
precipitated 
materials. 
Pre-clear the antibody 
at 20,000 ×g for 5 min 
at 4oC and use the 
supernatant for step 
2. 
   Rotate the device by 
180o to make use of 
the other membrane. 
  Use Vivaspin 
ultrafiltration device 
instead as it can 
concentrate antibody 
down to 5 µl. 
13 Antibody is lost after 
ultrafiltration. 
The membrane is 
damaged. 
Check the centrifugal 
force and do not 
touch the membrane 
with pipette tip. 
  The antibody is 
binding to the 
regenerated 
cellulose membrane. 
Use Vivaspin 
ultrafiltration device 
instead as it utilizes 
polyethersulfone 
rather than 
regenerated cellulose 
membrane. 
13 Antibody concentration is 
much higher than 
expected. 
The antibody 
solution contains 
stabilizing proteins 
such as BSA. 
Pre-purify the 
antibody using 0.2 ml 
Nab protein A/G spin 
kit 
Trim-Away by microinjection of mouse oocytes and pre-implantation embryos 
16(A)(iv)-(viii) mRNA mix mixes with the 
antibody mix within the 
capillary. 
The mRNA mix is 
loaded before the 
antibody mix. 
Load antibody mix 
before the mRNA mix. 
16(A)(xix)/ 
16(B)(ix)/ 
16(C)(ii)/ 
16(C)(vi) 
Microinjection needle or 
Femtotip II is clogged 
every few injections. 
Precipitated 
materials are loaded 
into the capillary. 
Pre-clear longer 
and/or break the tip 
more. 
  Precipitated 
materials are loaded 
into the Femtotip II. 
Pre-clear longer, 
break the tip more 
and/or use the ‘Clean’ 
function. 
  The antibody 
concentration is too 
Use 0.1% NP-40 
and/or inject a larger 
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high. volume of diluted 
antibody mix. 
 Oocytes and early embryos 
do not survive the 
microinjection. 
The GV is damaged. Inject close to the GV 
but do not penetrate 
the membrane of GV. 
  The opening of the 
microinjection 
needle is too wide. 
Adjust the program of 
the needle puller to 
obtain thinner 
microinjection 
needle. 
  Break the tip of the 
microinjection needle 
just enough for the 
mercury to flow to 
the tip. 
  The injection volume 
is too large. 
Do not inject more 
than 12 pl (~6%) for 
mouse oocytes. 
  The intracellular NP-
40 concentration is 
too high. 
Use 0.05% NP-40 
and/or inject less 
antibody mix. 
16(A)(xxi)/ 
16(B)(xi)/ 
16(C)(vii) 
Target protein is not 
degraded. 
The antibody does 
not recognize the 
antigen. 
Use another antibody. 
  TRIM21 does not 
recognize the 
antibody. 
Confirm that the 
antibody contains an 
exposed Fc-region or 
use another antibody.  
  The microinjection is 
not successful. 
Confirm that the 
microinjection needle 
or Femtotip II 
penetrates the 
plasma membrane 
and there is a 
cytoplasmic 
movement due to 
liquid outflow. 
  Oocytes and early 
embryos are treated 
with proteasome 
inhibitor such as 
MG132. 
Do not use 
proteasome inhibitor 
during incubation or 
apply it after 
incubation. 
 Depletion is not efficient 
or complete. 
The endogenous 
level of the target 
protein is too high. 
Incubate longer to 
allow degradation 
before the start of 
assay, use higher 
concentration of 
antibody and/or inject 
more antibody mix. 
  The expression level 
of Trim21 mRNA is 
Incubate longer to 
allow expression 
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too low. before the start of 
assay, use higher 
concentration of 
Trim21 mRNA and/or 
poly(A)-tail Trim21 
mRNA. 
  Trim21 mRNA is 
degraded. 
Make sure that all 
materials are handled 
in an RNase-free 
manner. 
 Oocytes and early embryos 
are not normally 
developing. 
Microinjected 
oocytes and early 
embryos are left 
outside the 
incubator for too 
long. 
Inject fewer oocytes 
and early embryos at 
a time and replace 
the medium in the 
microinjection 
chamber after each 
round of 
microinjection. 
  The injection volume 
is too large. 
Do not inject more 
than 12 pl (~6% of the 
oocyte volume) for 
mouse oocytes. 
  The intracellular NP-
40 concentration is 
too high. 
Use 0.05% NP-40 
and/or inject less 
antibody mix. 
  The mRNA mix 
and/or antibody mix 
is/are contaminated 
by embryo-toxic 
substance(s). 
Test the nuclease-free 
water and/or repeat 
the mRNA and/or 
antibody preparation. 
  The antibody has 
secondary inhibitory 
effects. 
Reduce the injection 
volume, antibody 
concentration and/or 
use another antibody. 
  Reporter mRNA(s) 
is/are 
overexpressed. 
Reduce the injection 
volume and/or mRNA 
concentration. 
29 Air bubbles are present in 
the Neon 10 µl Tip. 
Air bubbles are 
present in the 
sample/ inaccurate 
pipetting/ 
insufficient sample 
volume. 
Gently tap the sample 
tube to remove air 
bubbles prior to 
taking up sample into 
Neon 10 µl Tip/ 
ensure the 
electroporation 
reaction sample has a 
volume of 12.5 µl/ 
take up the sample 
into the Neon 10 µl 
Tip slower. 
32 Target protein is not 
degraded. 
The antibody does 
not recognize the 
Use another antibody. 
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antigen.
  The antibody does 
not recognise the 
native protein inside 
cells. 
Use an antibody that 
has been tested to 
work by 
immunofluorescence  
  The electroporated 
antibody cannot gain 
access to the target 
protein. 
Allow longer 
incubation time/ 
incubation of cells for 
at least one cell 
division allows 
degradation of 
retained nuclear 
target proteins. 
  TRIM21 does not 
recognize the 
antibody. 
Use whole IgG 
molecules from 
mammalian hosts. 
  Electroporation of 
antibody was not 
successful. 
Check the antibody 
concentration prior to 
electroporation/ 
check for arcing 
(sparks) during 
electroporation likely 
caused by air bubbles 
in the Neon Tip. 
  Cells are treated 
with proteasome 
inhibitor such as 
MG132. 
Do not use 
proteasome inhibitor 
during Trim-Away. 
 Depletion is not efficient 
or complete. 
The endogenous 
level of the target 
protein is too high. 
Incubate longer to 
allow degradation 
before the start of 
assay/ use higher a 
concentration of the 
antibody. 
  TRIM21 levels are 
too low. 
Use TRIM21-
overexpressing stable 
cell lines/ co-
electroporate 
recombinant TRIM21 
protein together with 
the antibody. 
 Cells have low survival 
rates. 
Arcing (sparks) 
occurs during 
electroporation. 
Ensure that there are 
no air bubbles in the 
Neon 10 µl Tip. 
  Cells were incubated 
for too long in Neon 
Buffer R 
Proceed to antibody 
electroporation 
within 10 min of 
resuspending cells in 
Neon Buffer R. 
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Anticipated results 
Generation of TRIM21 stable cell lines as described in Box 3 should result in all cells overexpressing 
TRIM21 diffusely in the cytoplasm (Fig. 2a,b and 2d,e). Representative results for Trim-Away assays in 
cell lines overexpressing TRIM21 are shown in Figure 2c and 2f. The expression and purification 
protocol described in box 4 should give TRIM21 protein yields of at least 1 mg/ml (Fig. 2g). Figure 2h 
shows Trim-Away of ERK1 in five different unmodified human cells lines by either electroporating 
anti-ERK1 antibody alone or together with recombinant TRIM21 protein. 
Representative results for a Trim-Away assay in mouse oocytes are shown in Figure 4. In the example 
shown, it can be observed that depletion of motor protein kinesin-5 (Eg5) by Trim-Away resulted in a 
monopolar spindle during meiosis I (MI) (Fig. 4a). This is consistent with inhibiting the motor activity 
of Eg5 with monastrol46. Subsequent expression of Eg5-meGFP from mRNA reverted the phenotype 
(Fig. 3d and 4b), confirming the specificity of Eg5 depletion by Trim-Away. 
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Figures 
 
Figure 1 | Schematic of the principle of Trim-Away. 
 
Figure 2 | Trim-Away in cell lines. (a and d) NIH3T3, NIH3T3-mCherry-mTRIM21, HEK293T and 
HEK293T-mCherry-hTRIM21 cell lines were analysed by flow cytometry. At least 2000 cells were 
counted for each condition. Percentages correspond to mCherry-positive cells falling within the gate 
drawn. (b and e) NIH3T3-mCherry-mTRIM21 and HEK293T-mCherry-hTRIM21 cells were imaged by 
confocal microscopy, detecting mCherry fluorescence. Scale bar, 50µm. (c) NIH3T3 and NIH3T3-
mCherry-mTRIM21 cell lines were electroporated with control IgG or anti-Pericentrin antibodies and 
analysed 16 hours later by immunoblotting. (f) HEK293T and HEK293T-mCherry-hTRIM21 cell lines 
were electroporated with PBS or anti-IKKα antibody and analysed 3 hours later by immunoblotting. 
(g) Coomassie-stained gel showing His-Lipoyl-hTRIM21 protein. Stars indicate bacterial contaminants 
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(*) and degradation products (**). (h) The indicated cell lines were electroporated with PBS, anti-
ERK1 antibody, His-Lipoyl-TRIM21, or anti-ERK1 + His-Lipoyl-TRIM21 and analysed 3 hours later by 
immunoblotting. Data in panels a-f and panel h were originally published in ref. 15. 
 
Figure 3 | Schematic of Trim-Away experiments in mouse oocytes. (a) For constitutive depletion, 
mouse oocytes are co-injected with Trim21 mRNA and antibody, and are allowed for expression of 
Trim21 and subsequent target protein degradation for 3 – 4 hours before release. (b) For acute 
depletion, mouse oocytes are first injected with Trim21 mRNA, and are allowed for expression of 
Trim21 for 3 – 4 hours before release. At the desired time point, the antibody is acutely injected into 
the oocytes. (c) For hydraulic-based microinjection system, the capillary is loaded with the first oil, 
antibody mix, the second oil, mRNA mix followed by the third oil. The liquids are taken up into the 
microinjection needle in the reverse order. (d) For rescue, mRNA encoding the degraded target 
protein is acutely injected into the oocytes. 
 
Figure 4 | Trim-Away in mouse oocytes. (a and b) 3D time-lapse imaging of mouse oocytes 
expressing  meGFP-MAP4 (green, microtubules) and H2B-mCherry (magenta, chromosomes), 
injected with Trim21 mRNA and control IgG or anti-Eg5 (Sigma-Aldrich, cat. no. HPA010568). Z-
projection, 5 sections, every 6 µm. Scale bar, 10 µm. Time, hour:min from nuclear envelope 
breakdown (NEBD). (c and d) 3D time-lapse imaging of Eg5-depleted mouse oocytes expressing 
mCherry-MAP4 (green, microtubules), injected with solvent or EG5-meGFP mRNA. Z-projection, 5 
sections, every 6 µm. Scale bar, 10 µm. Time, hour:min from NEBD. 
 
Box 1 Peptide pre-incubation assay (TIMING 2 – 4 days) 
This	Box	describes	 the	procedures	 for	pre-incubating	a	primary	antibody	with	 its	 immunizing	
peptide	prior	to	 immunofluorescence.	This	assay	allows	the	evaluation	of	non-specific	binding	
of	the	antibody	under	native	conditions.	
	
Reagents	
 Paraformaldehyde (4% (wt/vol) in PBS; VWR, cat. no. J61899) 
 Immunizing peptide (lyophilized; from solid-phase peptide synthesis by company such as 
GenScript) 
 Bovine serum albumin (BSA) solution (30% (wt/vol) in DPBS; Sigma-Aldrich, cat. no. A9576) 
 PBS tablets (Gibco, cat. no. 18912) 
 Triton X-100 solution (10% (vol/vol) in H2O; Sigma-Aldrich, cat. no. 93443) 
	
 
	
Reagent	Setup 
 PBT Add 1 g of PBS tablet and 5 ml of 10% (vol/vol) triton X-100 solution to 95 ml of water. 
Store at 4oC until use. 
 PBT-BSA Add 1 g of PBS tablet, 5 ml of 10% (vol/vol) triton X-100 solution and 10 ml of 30% 
(wt/vol) BSA solution to 85 ml of water. Store at 4oC until use 
	
	
Procedure	
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1. Add appropriate volume of solvent to dissolve the lyophilized peptide at a final concentration of 
133 μM.	
Δ	CRITICAL	STEP	Recombinant	protein	has	been	used	with	success	as	well,	albeit	at	a	higher	
cost.	
2. Fix the identical samples with 4% (wt/vol) paraformaldehyde in PBS for 15 – 30 min at 37oC. 
3. Permeabilize the samples in PBT overnight at 4oC. 
4. Block the samples in PBT-BSA overnight at 4 oC 
5. Mix the components tabulated below and incubate at 4oC overnight. 
Component	 Amount	per	reaction	(µl) Final	concentration	
1	mg/ml	(Primary)	Antibody	 0.2 10	µg/ml (66.7	nM)	
133	µM	Peptide	 0	(for	no-peptide	control)	or	
2	(for	peptide	pre-incubated	
sample)	
0	or	13.3	µM	(200X	of	
66.7	nM)	
PBT-BSA	 to	20
6. Pre-clear the mixes from step 5 by centrifuging at 20,000 ×g	for	5	min	at	4oC 
7. Incubate one sample with the pre-cleared mix without peptide from step 4 (i.e. no-peptide 
control) and the other sample with the pre-cleared mix with peptide from step 4 (i.e. peptide 
pre-incubated sample) overnight at 4oC. 
8. Wash the samples in PBT-BSA for 5 min at room temperature three times. 
9. Incubate the samples with secondary antibodies diluted in PBT-BSA for 1 hour at room 
temperature. 
10. Wash the samples in PBT for 5 min at room temperature three times. 
11. Image the samples in PBS. 
12. Assess non-specific bindings from the signal present in both the no-peptide control and peptide 
pre-incubated sample. 
 
Box 2 Trim21 and reporter mRNA preparation (TIMING 8 hours) 
This	Box	describes	the	procedures	for	preparing	mRNAs	encoding	Trim21	and	reporters	for	live-
cell	 imaging.	The	resulting	mRNAs	are	suitable	 for	microinjection	 into	mouse	oocytes	or	early	
embryos	for	expression.	
 
Reagents 
 pGEMHE-mCherry-mTrim21 (Addgene plasmid #105522) 
 pGEMHE-mEGFP-mTrim21ΔRING-Box (Addgene plasmid #105520) 
 pGEMHE-mCherry-mTrim21ΔRING-Box (Addgene plasmid #105523) 
 pGEMHE-mEGFP-mTrim21ΔPRYSPRY (Addgene plasmid #105521) 
 pGEMHE-mCherry-mTrim21ΔPRYSPRY (Addgene plasmid #105524) 
 Nuclease-free water (not DEPC-treated; Invitrogen, cat. no. AM9930) 
 CutSmart Buffer (NEB, cat. no. B7204S) 
 AscI (NEB, cat. no. R0558S or R0558 L) 
 Glycogen (RNA grade; Thermo Scientific, cat. no. R0551) 
 Phenol-chloroform-isoamyl alcohol (IAA) mixture (25:24:1; Sigma-Aldrich, cat. no. 77617) 
 Sodium acetate buffer solution (3 M; pH 7.0; Sigma-Aldrich, cat. no. S2404) 
 Ethanol (Sigma-Aldrich, cat. no. 51976) 
 Liquid nitrogen 
 HiScribe T7 ARCA mRNA kit (with tailing; NEB, cat. no. E2060S) 
 TURBO DNase (2 U/µl; Invitrogen, cat. no. AM2238) 
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 NucleoSpin RNA Clean-up XS (Macherey-Nagel, cat. no. 740903) 
 Phenol-chloroform-IAA mixture (125:24:1; Sigma-Aldrich, cat. no. 77619) 
 Ethylenediaminetetraacetic acid solution (0.5 M; pH 8.0; Sigma-Aldrich, cat. no. 03690) 
 Sodium acetate buffer solution (3 M; pH 5.2; Sigma-Aldrich, cat. no. S7899) 
 Sodium dodecyl sulfate (SDS) solution (10% (wt/vol) in H2O; Sigma-Aldrich, cat. no. 71736) 
 
Equipment 
 Snaplock microcentrifuge tube (1.5 ml; RNase-/DNase-free; nonpyrogenic; Corning, cat. no. 
MCT-150-C) 
 Centrifuge 5424 R (refrigerated; Eppendorf, cat. no. 5404000413) 
 NanoDrop 2000 spectrophotometer (Thermo Scientific, cat. no. ND-2000) 
 
Reagent Setup 
 0.25 M sodium acetate-5 mM EDTA-0.5% (wt/vol) SDS Add 0.1 ml of 0.5 M EDTA solution, 0.5 
ml of 10% (wt/vol) SDS solution and 0.833 ml of 3 M sodium acetate buffer solution (pH 5.2) to 
8.567 ml of nuclease-free water. Divide into 1 ml aliquots and store at -20oC until use. 
 70% (vol/vol) ethanol Add 35 ml of ethanol to 15 ml of nuclease-free water. Store at -20oC until 
use. 
 
Equipment Setup 
 NanoDrop 2000 spectrophotometer Set up the NanoDrop 2000 spectrophotometer according 
to the manufacturer’s instructions. 
 
Procedure 
1. Linearization and purification of DNA template (Steps 1-12): Mix	 the	 components	 tabulated	
below	in	a	1.5	ml	nuclease-free	tube	and	incubate	at	37oC	for	1	hr.	
Component	 Amount	per	reaction	(µl) Final	concentration	
Nuclease-free	water	 20	
0.5	µg/µl	Trim21	or	reporter	
construct	(in	pGEMHE)	
20	 0.2	µg/µl
10X	CutSmart	Buffer	 5	 1X
10	U/µl	AscI	 5	 1	U/µl
Δ	CRITICAL	STEP	We	generally	use	pGEMHE	as	the	vector	because	it	contains	a	T7	promoter,		
multiple	cloning	sites	flanked	by	5’-	and	3’-untranslated	region	(UTRs)	of	Xenopus	β-globin	gene,	
a	short	stretch	of	~35	bp	poly(A)	sequence	and	linearization	sites.	Constructs	in	other	vectors	
such	as	pCS2	can	also	be	used,	but	the	translation	efficiency	may	be	lower	due	to	the	lack	of	the	
5’	and	3’	UTRs,	and	poly(A)	tailing	may	be	required.	
2. Add	0.5	µl	glycogen,	150	µl	nuclease-free	water	and	200	µl	phenol-chloroform-IAA	(pH	8.0)	
to	terminate	the	linearization	reaction.	
Δ	CRITICAL	STEP	Addition	of	glycogen	as	co-precipitant	is	optional,	but	the	yield	of	precipitated	
DNA	is	higher.	
Δ	CRITICAL	STEP	Phenol-chloroform-IAA	is	saturated	and	stored	with	an	equilibration	buffer.	
Do	not	take-in	the	upper	aqueous	layer	to	avoid	dilution.	
3. Invert	end-to-end	to	mix	well	and	centrifuge	at	20,000	×g	for	5	min	at	room	temperature.	
4. Transfer	~180	µl	of	the	upper	phase	to	a	new	1.5	ml	nuclease-free	tube,	 add	20	µl	of	3	M	
sodium	acetate	(pH	7.0)	and	400	µl	of	ice-cold	100%	ethanol.	
Δ	CRITICAL	STEP	Do	not	use	100%	isopropanol	as	more	salts	will	be	precipitated.	
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5. Invert	end-to-end	to	mix	well	and	snap-freeze	in	liquid	nitrogen.	
6. Centrifuge	at	20,000	×g	for	30	min	at	4oC.	
Δ	CRITICAL	STEP	Start	centrifugation	before	the	mixture	is	thawed.	
7. Discard	the	supernatant	and	add	1	ml	ice-cold	70%	(vol/vol)	ethanol	in	nuclease-free	water.	
8. Invert	end-to-end	to	mix	well	and	centrifuge	at	20,000	×g	for	1	min	at	4oC.	
Δ	CRITICAL	STEP	Do	not	vortex	to	avoid	fragmentation	of	the	pellet. 
9. Discard	~900	µl	of	the	supernatant	and	centrifuge	at	20,000	×g	for	30	sec	at	4oC.	
Δ	CRITICAL	STEP	This	step	is	necessary	for	avoiding	ethanol	carryover.	
10. Discard	the	rest	of	the	supernatant	and	air-dry	for	3	min	at	room	temperature.	
Δ	CRITICAL	STEP	After	drying,	the	centre	of	the	pellet	should	remain	white	with	the	edge	being	
transparent.	Over-drying,	as	indicated	by	a	completely	transparent	pellet,	should	be	avoided.	
11. Add	6	µl	nuclease-free	water	and	pipette	up-and-down	to	fully	dissolve	the	pellet.	
12. Use	 1	 µl	 to	 measure	 the	 DNA	 concentration	 with	 a	 NanoDrop	 spectrophotometer.	 We	
typically	recover	~7	–	8	µg	linearized	DNA.	
	PAUSE	POINT	Linearized	DNA	can	be	stored	at	-20oC	until	use.	
13. In vitro transcription of capped mRNA	 (Step	13):	Mix	 the	 components	 tabulated	below	 in	 a	
1.5	ml	nuclease-free	tube	and	incubate	at	40oC	for	4	hr.	
Component	 Amount	per	reaction	(µl) Final	concentration	
Nuclease-free	water	 19	or	21.5
~1.2	µg/µl	Linearized	DNA	 2.5	(for	mRNA	of	<6	kb)	or	5	
(for	mRNA	of	≥6	kb)	
0.05	or	0.1	µg/µl	
2X	ARCA/NTP	mix	 30	 1X
T7	RNA	polymerase	mix	 6	
Δ	 CRITICAL	 STEP	 We	 use	 the	 HiScribe	 T7	 ARCA	 mRNA	 kit	 (with	 tailing)	 for	 successful	
transcription	of	full-length	mRNAs	of	up	to	12	kb	at	high	yield.	Other	in	vitro	transcription	kits	
can	also	be	used,	but	the	ratio	of	ARCA:GTP:CTP:ATP:UTP	should	be	adjusted	from	0.8:0.2:1:1:1	
to	4:1:1:1:1.	
Δ	CRITICAL	STEP	For	constructs	with	other	promoters	such	as	T3	or	SP6,	corresponding	RNA	
polymerase	should	be	used.	
14. Removal of DNA template (Step 14):	Add	3	µl	of	2	U/µl	TURBO	DNase	and	 incubate	at	37oC	
for	15	min.	
Δ	CRITICAL	STEP	Other	DNase	I	can	be	used	as	well.	
15. Optional: Poly(A) tailing of mRNA (Steps 15-16): Mix	 components	 tabulated	 below	 and	
incubate	at	37oC	for	3	min.	
Component	 Amount	per	reaction	(µl) Final	concentration	
Nuclease-free	water	 192
Mix	from	step	13	 63	
10X	 Poly(A)	 polymerase	
reaction	buffer	
30	 1X
Δ	CRITICAL	STEP	We	generally	omit	step	15	and	16	when	we	synthesize	mRNAs	from	pGEMHE-
based	 plasmids,	 add	 237	 µl	 nuclease-free	 water	 and	 directly	 proceed	 to	 step	 17.	 However,	
poly(A)	 tailing	 can	 be	 advantageous	 for	 assays	 with	 a	 longer	 time	 frame	 (i.e.	 >24	 hr)	 or	 for	
mRNAs	transcribed	from	constructs	without	a	short	stretch	of	poly(A)	tail.	
16. Add	15	µl	of	Poly(A)	polymerase	and	incubate	at	37oC	for	30	min. 
17. Removal of free nucleotides (Step 17):	 Purify	 the	mRNA	using	NuceloSpin	RNA	Clean-up	XS	
and	elute	with	160	µl	nuclease-free	water.	
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Δ	CRITICAL	STEP	This	 step	 can	 be	 omitted,	 but	 then	 the	 final	 RNA	 concentration	 cannot	 be	
directly	determined	with	a	NanoDrop	spectrophotometer	due	to	free	nucleotide	contamination.	
18. Purification of mRNA (Steps 18-23):	Add	0.5	µl	glycogen,	40	µl	of	0.25	M	sodium	acetate-5	mM	
EDTA-0.5%	(wt/vol)	SDS	and	200	µl	phenol-chloroform-IAA	(pH	4.0).	
Δ	CRITICAL	STEP	Addition	of	glycogen	as	co-precipitant	is	optional,	but	the	yield	of	precipitated	
mRNA	is	higher.	
Δ	CRITICAL	STEP	Phenol-chloroform-IAA	is	saturated	and	stored	with	an	equilibration	buffer.	
Do	not	take-in	the	upper	aqueous	layer	to	avoid	dilution.	
19. Invert	end-to-end	to	mix	well	and	centrifuge	at	20,000	×g	for	5	min	at	room	temperature.	
20. Transfer	~180	µl	of	the	upper	phase	to	a	new	1.5	ml	nuclease-free	tube	and	add	360	µl	of	
ice-cold	100%	ethanol.	
Δ	CRITICAL	STEP	Do	not	use	100%	isopropanol	as	more	salts	will	be	precipitated.	
21. Repeat	step	5	to	10.	
22. Add	11	µl	of	nuclease-free	water	and	pipette	up-and-down	to	fully	dissolve	the	pellet.	
23. Use	1	µl	to	measure	the	RNA	concentration	with	a	NanoDrop	spectrophotometer.	
Δ	CRITICAL	STEP	 RNA	 concentration	 can	 also	 be	 determined	with	 other	 techniques	 such	 as	
agarose	 gel	 electrophoresis	 and	 comparison	 with	 RNA	 markers	 of	 known	 concentration	 or	
fluorescence-based	Qubit	RNA	assays.	
Δ	CRITICAL	STEP	We	typically	obtain	mRNA	at	~1	–	3	µg/µl.	
	PAUSE	POINT	mRNA	should	be	divided	into	0.6	µl	single-use	aliquots	and	can	be	stored	at	-
80oC	as long as no signs of mRNA degradation can be seen. 
 
Box 3 Preparation of TRIM21 stable cell lines (TIMING 2 – 3 weeks) 
Though TRIM21 is near-universally expressed, its expression level varies between cell types. 
As TRIM21 is degraded alongside the antibody and target antigen during Trim-Away, levels of 
endogenous TRIM21 may be insufficient to elicit complete degradation of target antigen, 
especially where the target antigen is abundant. This can be remedied by the constitutive 
expression of TRIM21 stably integrated into the target cell genome. Here we describe a 
protocol for stable cell line generation by transduction with pseudotyped lentiviral particles. 
However, alternative approaches for stable cell line generation may also be used.  
 
Reagents 
 DMEM (high glucose; GlutaMAX; Gibco, cat. no. 31966) 
 Fetal bovine serum (Gibco, cat. no. 10270) 
 DPBS (no calcium; no magnesium; Gibco, cat. no. 14190) 
 Trypsin-EDTA (0.05% (wt/vol), phenol red; Gibco, cat. no. 25300) 
 Opti-MEM I reduced serum medium (Gibco, cat. no. 31985) 
 psPAX2 (Addgene plasmid #12260) 
 pSMPP-mCherry-hTRIM21 (Addgene plasmid #104972) 
 pSMPP-mCherry-mTrim21 (Addgene plasmd #104971) 
 pMD2.G (Adddgene plasmid #12259) 
 FuGENE 6 transfection reagent (Promega, cat. no. E2691) 
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 Polybrene (Santa Cruz Biotechnology, cat. no. sc-134220) 
 Puromycin dihydrochloride (Gibco, cat. no. A1113803) 
 
Equipment 
 Corning tissue-culture treated culture dishes (100 mm × 20 mm; Sigma-Aldrich, cat. no. 
CLS430167) 
 10 ml syringe (BD Plastipak, cat. no. 302188) 
 33 mm Ezee syringe filters (0.45 μm; PVDF; sterile; Elkay, cat. no. E25-PV45-50S) 
 Corning Costar TC-treated multiple well plates (6 wells; clear; polystyrene plate; flat bottom; 
Sigma-Aldrich, cat. no. CLS3516-50E) 
 Corning Costar TC-treated multiple well plates (24 wells; flat bottom; Sigma-Aldrich, cat. no. 
CLS3527) 
 
Reagent Setup 
 DMEM supplemented with 1X GlutaMAX and 10% (vol/vol) fetal bovine serum Add 55 ml of 
fetal bovine serum to 500 ml of DMEM. Store at 4oC until use. 
 
Procedure 
! CAUTION  Ensure that virus work takes place at an appropriate level of biosafety according 
to institutional and national regulations. 
1. Seed 2.5 x106 HEK293T cells in a 10 cm dish containing 10 ml of DMEM 
supplemented with 1X GlutaMAX and 10% (vol/vol) fetal bovine serum. 
2. Incubate the cells for 16 – 24 h at 37°C in a 5% CO2 atmosphere. 
3. In a sterile 1.5 ml reaction tube, prepare 200 μL of Opti-MEM I, 2 μg of HIV GagPol 
expression plasmid (e.g. psPAX2), 2 μg of TRIM21 construct in lentiviral transfer 
vector (e.g. pSMPP-mCherry-hTRIM21) and 1 μg of VSV-G glycoprotein expression 
plasmid (e.g. pMD2.G).  
4. Mix the plasmids well by gentle vortexing and bring to the bottom of the tube with a 
brief spin in a microcentrifuge.  
5. Add 12 µl of FuGENE 6 transfection reagent to the plasmids and mix immediately by 
flicking. Bring liquid to the bottom of the tube with a brief spin in a microcentrifuge.  
6. Incubate the transfection mix for 20 min at room temperature.  
7. Add the transfection mix dropwise to the centre of the dish of HEK293T cells with 
gentle swirling. 
Δ CRITICAL STEP Mixing by pipetting or vigorous agitation should be avoided as it 
may dislodge HEK293T cells from tissue culture dishes.  
8. Incubate the cells for 16 – 24 h at 37°C in a 5% CO2 atmosphere. 
9. Gently remove the media and replace with fresh, pre-warmed DMEM supplemented 
with 1X GlutaMAX and 10% (vol/vol) fetal bovine serum, and return cells to the 
incubator for a further 48 h. 
10. (Optional) Examine the cells under a fluorescence microscope to ensure high levels 
of mCherry-hTRIM21 expression in virus producing cells resulting from transfection 
and single cycle re-infection.  
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11. Harvest the supernatant directly into a 10 ml syringe and filter at 0.45 µm, separate 
into 1 ml aliquots and store the virus particles at -80°C.  
	PAUSE	POINT	Viral	particles	can	be	stored	indefinitely	at	-80°C	
12. Seed adherent target cells at 1 x105 per well in 6 well plates in appropriate medium. 
Suspension cells can be seeded in 24 well plates in their normal media with 
polybrene at 10 μg/ml and transduced immediately (step 15). 
13. Incubate the cells 16 – 24 h at 37°C in a 5% CO2 atmosphere.  
14. Replace the media with fresh media containing 10 μg/ml polybrene (2X of final 
concentration).  
15. Thaw the virus supernatant at room temperature. 
16. On the first transduction of a new cell type, or after production of a new batch of 
virus supernatant, add virus at a range of concentrations to determine the optimal 
level for low multiplicity transduction (less than 0.1 transducing particles per cell). 
Prepare a five-fold serial dilution of virus in media such that each well will receive 1, 
5, 25, 125, 625 μL of virus. Add virus to cells in a volume equal to the plating media 
such that final polybrene concentration is 5 μg/ml. Include a control well that does 
not receive virus. 
17. Incubate the cells for 48 h at 37°C in a 5% CO2 atmosphere.  
18. Analyse for transgene expression by fluorescence microscopy or flow cytometry. 
Select conditions where <10% of cells are expressing mCherry-TRIM21 to minimise 
the number of multiply-transduced cells. 
19. Add puromycin to the cells at an appropriate concentration for the cell type, typically 
0.5 – 5 µg/ml. 
20. After 1 week of selection, all untransduced cells and the untreated control well 
should be killed. Expand the cell population for freezing and for use in Trim-Away 
experiments. 
Δ CRITICAL STEP Regularly ensure that the distribution of mCherry-TRIM21 is diffuse 
and cytoplasmic by fluorescence microscopy (Fig. 4b and 4e). Large crescent-shaped 
aggregates of mCherry-TRIM21 that are non-functional can form if levels of 
expression are too high or cells become over-confluent. This seems to be a cell type-
specific phenomenon, and occurs in cell types where expression from viral promoters 
is particularly high, for instance in HEK293 cells. In this case, consider FACS sorting 
low mCherry-positive cells or deriving clonal lines and selecting low expressing 
colonies. Alternatively, consider using a tetracycline-inducible promoter to drive 
TRIM21 expression. 
 
Box 4 Preparation of recombinant TRIM21 protein (3 days) 
This Box describes the procedure for expression and purification of full-length human 
TRIM21 protein His-Lipoyl-hTRIM21 (Fig. 2g). His-Lipoyl-hTRIM21 is expressed from a T7-
promoter driven bacterial expression plasmid HLTV-hTRIM21. HLTV-hTRIM21 is available 
from Addgene (see Reagents) and is a low copy number ampicillin-resistant plasmid with an 
N-terminal His tag that can be optionally cleaved via TEV protease. 
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Reagents 
 OverExpress C41(DE3) chemically competent cells (Sigma-Aldrich, cat. no. CMC0017) 
 HLTV-hTRIM21 (Addgene plasmid #104973) 
 LB-Agar Miller (Formedium, cat. no. LMM02) 
 2XTY media (Formedium, cat. no. YDB) 
 D-(+)-Glucose (Sigma-Aldrich, cat. no. G8270) 
 Ampicillin sodium salt (MELFORD, cat. no. A0104) 
 IPTG (MELFORD, cat. no. MB1008) 
 Bugbuster plus Benzonase (Merck Millipore, cat. no. 70750-3) 
 cOmplete, EDTA-free protease inhibitor cocktail (Sigma-Aldrich, cat. no. 04693132001) 
 Trizma base (Sigma-Aldrich, cat. no. T1503) 
 Sodium chloride (Sigma-Aldrich, cat. no. S3014) 
 Ni-NTA agarose (Qiagen, cat. no. 30210) 
 Imidazole (Sigma-Aldrich, cat. no. I5513) 
 
Equipment 
 Poly-Prep Chromatography Column (Bio-Rad, cat. no 7311550) 
 ÄKTA pure (GE Healthcare Life Sciences) 
 HiLoad 26/600 Superdex 200 pg (GE Healthcare Life Sciences, cat. no. 28989336) 
 
Reagent Setup 
 100 mg/ml ampicillin Add 10 g of ampicillin sodium salt to 100 ml of sterile water. Filter at 0.45 
µm. Divide into 10 ml aliquots and store at -20oC until use. 
 LB agar plates supplemented with 100 µg/ml ampicillin Add 40 g of LB-Agar Miller to 1 L of 
sterile water. Autoclave at 120 oC for 15 min. Cool down briefly and add 1 ml of 100 mg/ml 
ampicillin before pouring plates. 
 2xTY medium Add 31 g of 2XTY media to 1 L of sterile water. Autoclave at 120°C for 15 min. 
 0.1 M IPTG Add 2.38 g of IPTG to 100 ml of sterile water. Filter at 0.45 µm. Divide into 10 ml 
aliquots and store at -20oC until use. 
 10% (wt/vol) glucose Add 10 g of glucose to 100 ml of sterile water. Autoclave at 120oC for 15 
min. 
 1 M Tris (pH 8.0) Add 12.1 g of trizma base to 90 ml of sterile water. Adjust the pH to 8.0 and 
top up to 100 ml with sterile water. Store at room temperature until use. 
 5 M NaCl Add 29.2 g of sodium chloride to 90 ml of sterile water. Top up to 100 ml with sterile 
water. Store at room temperature until use. 
 PBS (pH 8.0) Add 5 g of PBS tablet to 450 ml of sterile water. Adjust the pH to 8.0 and top up to 
100 ml with sterile water. Store at room temperature until use. 
 3 M Imidazole Add 102.1 g of imidazole to 450 ml of sterile water. Adjust the pH to 8.0 and top 
up to 500 ml with sterile water. Store at room temperature until use. 
 Wash buffer (20 mM Tris (pH 8.0)-200 mM NaCl-10 mM imidazole) Add 1.7 ml of 3 M 
imidazole, 10 ml of 1 M Tris (pH 8.0) and 20 ml of 5 M NaCl to 468.3 ml of sterile water. Store at 
room temperature until use. 
 20 mM Tris (pH 8.0)-200 mM NaCl Add 10 ml of 1 M Tris (pH 8.0) and 20 ml of 5 M NaCl to 470 
ml of sterile water. Store at room temperature until use. 
 
Equipment Setup 
 ÄKTA pure The HiLoad 26/600 Superdex 200 pg column is setup according to manufacturer’s 
instructions 
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Procedure 
1. Freshly transform C41(DE3) cells with HLTV-hTRIM21, plate the transformed cells 
onto a LB-agar plate supplemented with 100 µg/ml ampicillin overnight at 37°C. 
2. Pick colonies and inoculate overnight cultures in 25 mL 2XTY supplemented with 2% 
(wt/vol) glucose and 100 µg/ml ampicillin. Shake at 220 rpm at 37°C. 
3. Inoculate 1 L of 2XTY media with 10 ml of overnight culture, supplement with 0.1% 
(wt/vol) glucose and 100 µg/ml ampicillin. Shake at 220 rpm at 37°C. 
4. At OD600 0.8 – 1.2 (after ~3 h), induce with 0.1 mM IPTG and reduce the temperature 
to 22°C.   
Δ CRITICAL STEP Induction at ODs greater than 1.2 or overnight growth at higher 
temperatures will dramatically reduce yields. 
5. Next day, harvest the cells in 1 L centrifuge bottles by centrifuging at 5.000 xg for 20 
min at 4°C (e.g. using RC3B rotor). Discard the media. 
	PAUSE POINT Bacterial pellets can be frozen at -20°C, and protein preparation can 
be continued later. 
6. Re-suspend the cells in 20 ml of Bugbuster + ½ crushed complete, EDTA-free protease 
inhibitor cocktail tablet per centrifuge tube. Add 1 M Tris (pH 8.0) to a final 
concentration of 20 mM and 5 M NaCl to 200 mM. 
7. Keep the cells in 50 ml centrifuge tubes (40 ml per tube) on ice-water.  Sonicate a 
minimum of 2 min with 10 s pulse followed by 10 s rest. 
Δ CRITICAL STEP Sonicated solution should be carefully monitored so that it does not 
become warm. Successful sonication is indicated by a noticeable reduction in the 
viscosity of the solution. 
8. Spin down in SS34 rotor at 20.000 xg for 40 min at 4°C.  Carefully decant the 
supernatant.  Proceed to Step 9 during centrifugation. 
9. In the meantime, wash 10 ml of Ni-NTA agarose in 50 ml PBS (pH 8.0).  Spin at 2.000 
xg for 3 min at room temperature and discard the supernatant. Repeat once.  
Δ CRITICAL STEP Centrifugation of Ni-NTA beads at higher revolutions for longer time 
periods will compress the resin and reduce its binding capacity. 
10. Add Ni-NTA agarose to cleared supernatant from step 8 in centrifuge tubes, 
supplement with 10 mM imidazole and rotate to allow mixing at 4°C for ~1 h. 
11. Spin down the resin at 2.000 xg for 3 min at 4°C and discard the supernatant.  
12. Resuspend the resin in 40 ml wash buffer, re-spin and discard the supernatant. 
Repeat this step once. 
13. Decant the washed resin to an empty gravity flow column. Wash the resin in place 
with 2 bed volumes of wash buffer. 
14. Elute the protein from resin with wash buffer supplemented with 300 mM imidazole. 
15. Analyse the eluted protein by SDS-PAGE to ensure that the purification has been 
successful. This should be visible as a single band running at ~66 kDa following 
Coomassie staining (Figure 2g). If so, proceed to step 16. 
16. Apply eluted protein to an S200 gel filtration column equilibrated with 20 mM Tris 
(pH 8.0)-200mM NaCl. Select the size of the S200 column depending on the volume 
of eluate and total amount of protein to be purified. Follow the manufacturer’s 
guidelines for column capacity and flow rate.  
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Δ CRITICAL STEP Eluted protein will not remain stable under high concentration of 
imidazole for prolonged periods, so it must be immediately buffer exchanged, 
desalted or gel-filtrated into 20 mM Tris (pH 8.0)-200mM NaCl. 
Δ CRITICAL STEP Soluble aggregated materials will elute in the void volume of the 
column and should be discarded.  
17. Analyse the peak fractions by SDS-PAGE to ensure that the correct peak is collected 
and to determine which fractions should be combined. 
Δ CRITICAL STEP TRIM21 is an elongated molecule with a large Stokes radius; if 
molecular weight standards are used to guide fraction collection, then note that 
TRIM21 will behave as if it is a trimer (i.e. 3X of its expected molecular weight (~165 
kDa)) in an S200 gel filtration column. 
Concentrate the combined fractions of TRIM21 using 50 kDa cut-off centrifugal filter 
units, aliquot them and snap freeze them in liquid nitrogen.   
Δ CRITICAL STEP Protein solution should be carefully monitored during centrifugation 
and regularly mixed to prevent super-concentration at the cellulose membrane. 
PAUSE POINT The purified protein can be stored at -80oC as long as no signs of 
protein degradation can be seen. 
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